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ABSTRACT 
JASON B. COOK: Ethanol Alters the GABAergic Neuroactive Steroid (3α,5α)-3-
hydroxypregnan-20-one (3α,5α-THP or Allopregnanolone) at Local Brain Sites: 
Significance of Local 3α,5α-THP Increases in the Ventral Tegmental Area 
(Under the direction of Dr. A. Leslie Morrow) 
 
 Neuroactive steroids are endogenous modulators of neuronal activity that 
modulate central nervous system inhibitory tone and influence motivation and emotional 
behaviors. The inhibitory neuroactive steroid (3,5)-3-hydroxypregnan-20-one (3α,5α-
THP or allopregnanolone) is a potent positive modulator of γ-aminobutyric acid type A 
(GABAA) receptors. In rats, systemic ethanol administration increases 3α,5α-THP in the 
blood plasma, cerebral cortex, and hippocampus. Ethanol-induced increases of 3α,5α-
THP contribute to the behavioral and neurophysiological effects of ethanol in rats and the 
subjective effects of alcohol in humans. Previous in vivo studies suggest that ethanol-
induced increases of 3α,5α-THP are dependent on the adrenal glands, but in vitro studies 
suggest ethanol produces local synthesis of 3α,5α-THP. Furthermore, limitations in 
steroid assays have prevented the study of ethanol-induced changes of 3α,5α-THP in 
many of the brain regions implicated in alcoholism. The first aim of this project used 
3α,5α-THP immunohistochemistry (IHC) to determine ethanol effects on cellular levels 
of 3α,5α-THP across the rat brain, and determine the role of the adrenal glands in these 
effects. We showed that ethanol produces divergent, brain region specific, effects on 
cellular 3α,5α-THP levels. We also showed that ethanol can increase or decrease local 
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brain levels of 3α,5α-THP independent of adrenal activation in subcortical brain regions, 
but increases of 3α,5α-THP in the medial prefrontal cortex (mPFC) are dependent on the 
adrenal glands. Previous studies have shown that systemic 3α,5α-THP can reduce ethanol 
reinforcement and consumption. However, systemic 3α,5α-THP is metabolized rapidly 
and can produce sedation, limiting therapeutic value. Therefore, in aim 2 we used gene 
delivery to drive local neuroactive steroid synthesis in the nucleus accumbens (NAc) or 
ventral tegmental area (VTA), which are both implicated in ethanol reinforcement and 
consumption. We showed that adeno-associated viral vector-mediated local increases of 
3α,5α-THP in the VTA were associated with a long-term reduction in ethanol 
reinforcement and consumption. Further investigation showed that 3α,5α-THP is located 
in tyrosine hydroxylase (TH) positive and negative neurons, but not astrocytes in the 
VTA. These studies showed that ethanol can produce divergent effects on local brain 
levels of 3α,5α-THP and increasing local levels of 3α,5α-THP in the VTA is associated 
with reduced ethanol reinforcement and consumption. 
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 GENERAL INTRODUCTION CHAPTER 1.
 
ALCOHOLISM: SIGNIFICANCE OF THE PROBLEM 
 Alcohol drinking has been prevalent throughout human history and is often a part 
of social activities and celebrations. In the United States, most individuals will drink 
alcohol in their lifetime and moderate alcohol consumption is common. However, 
excessive alcohol use is currently one of the most costly public health issues in the 
United States, and indeed, throughout the world. The Diagnostic and Statistical Manual 
of Mental Disorders (American Psychiatric Association, 2013) classifies alcohol use 
disorders as a problematic pattern of alcohol use leading to clinically significant 
impairment or distress that includes at least two of the following criteria within a 12 
month period: alcohol tolerance, withdrawal symptoms, drinking more or longer than 
intended, craving or a strong desire for alcohol, inability to control use, a large amount of 
time spent seeking alcohol or recovering from use, missing important 
social/occupational/recreational activities due to alcohol use, physically hazardous use, 
continuing use despite knowledge of persistent or recurrent physical or psychological 
problems caused by alcohol, or alcohol use causes failure to fulfill major obligations at 
work, home, or school. The diagnostic results then specify if the alcohol use disorder is 
mild (2-3 symptoms), moderate (4-5 symptoms), or severe (6 or more symptoms). Based 
on the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC) 
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approximately 18 million people suffer from alcohol use disorders in the United States. 
Excessive alcohol consumption is the third leading preventable cause of death in the 
United States (Mokdad et al., 2004), and the economic impact of alcohol abuse has been 
estimated to be approximately $235 billion per year (Rehm et al., 2009). 
 The causes of alcohol use disorders are not known but likely are attributable to 
many genetic and environmental influences that increase an individual’s susceptibility to 
develop these disorders. Genetic factors have been associated with an increased 
susceptibility for developing alcohol use disorders. For example, having a positive family 
history of alcoholism or low sensitivity to alcohol’s effects are associated with an 
increased incidence of alcohol use disorders (Schuckit, 2000). However, in some Asian 
populations the presence of a polymorphism in the alcohol metabolizing enzymes, 
alcohol or aldehyde dehydrogenase, can be protective against developing alcohol use 
disorders (Thomasson et al., 1991). An early age of onset of drinking is also a predictor 
of future development of alcohol use disorders (Dawson et al., 2008). Finally, as with 
other drugs of abuse, the incidence of men with alcohol use disorders is higher than that 
of women (Grant et al., 2004). 
 Alcoholism is a chronic, lifelong disorder, which is inherently difficult to treat. 
Over the last several decades biomedical research has focused on determining the 
potential genetic and neurobiological mechanisms that contribute to excessive alcohol 
consumption. Although much has been learned about the neurobiology and genetics of 
alcoholism, the pharmacological treatments for alcohol use disorders are currently 
limited. The three available treatments in the United States are disulfuram, naltrexone, 
and acamprosate. These treatments are efficacious in some individuals, but many 
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alcoholics do not respond to any of these drugs. Therefore, it is crucial to develop many 
different treatments for alcohol use disorders, since treatments will most likely only be 
effective in some individuals. In the future, an individualized medicine approach appears 
promising since genetic differences can determine the effectiveness of a particular 
pharmacological treatment (Johnson et al., 2013; Thorsell, 2013).  
EFFECTS OF ALCOHOLISM ON THE HUMAN BRAIN 
 Alcohol affects most cells of the body but the behavioral effects and addictive 
properties of alcohol are thought to be mediated by the central nervous system (CNS). 
Alcoholism produces brain dysfunction and structural abnormalities. It was originally 
observed in postmortem studies that alcoholism causes brain shrinkage. The reduction in 
brain volume in human alcoholics is thought to be due to reduced white matter 
predominantly, but there is also loss of grey matter in some regions (Harper, 1998). 
Advances in neuroimaging have led to increased knowledge about the effects of alcohol 
on brain structure and function in live alcoholics. Magnetic resonance imaging (MRI) has 
been used to show that chronic alcohol use decreases volume in the anterior hippocampus, 
caudate/putamen, nucleus accumbens (NAc), thalamus, corpus collosum, and cerebellum 
(Sullivan and Pfefferbaum, 2005). Furthermore, MRI and functional MRI studies suggest 
the deficits in brain volume and white matter underlie the cognitive and motor 
dysfunction observed in alcoholics (Sullivan and Pfefferbaum, 2005). The pathology of 
alcoholic neurodegeneration is not understood but is likely due to many different factors, 
such as neuroinflammation, excitotoxcicity, and changes in expression of myelin proteins.  
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EFFECTS OF ALCOHOL ON CNS FUNCTION 
 Alcohol (ethyl alcohol or ethanol) is a very promiscuous drug that produces a 
plethora of effects in the body. Animal models and in vitro cell and slice cultures have 
been used to investigate the actions of ethanol in the brain. Multiple lines of biomedical 
research have determined that ethanol alters many neurotransmitter systems including 
dopamine, serotonin, γ-aminobutyric acid (GABA), glycine, and glutamate. Determining 
sites where ethanol produces its pharmacological effects is difficult since it is such a 
small molecule and physiological effects require a large dose. Nonetheless, 
electrophysiological studies have shown that ethanol alters conductance at multiple cell 
membrane bound ion channels. At physiologically relevant doses, ethanol enhances 
GABA type A (GABAA) receptor action (Suzdak et al., 1986) and inhibits excitatory 
glutamateric N-Methyl-D-aspartic acid (NMDA) receptors (Lovinger et al., 1989). 
Effects of ethanol at GABAA receptors are thought to mediate the anxiolytic and sedative 
effects of ethanol, while antagonism of NMDA receptors may contribute to ethanol’s 
impairing effects on cognition and memory. Ethanol also produces actions at 
acetylcholine nicotinic (Yu et al., 1996), glycine (Ye et al., 2001), and serotonin receptors 
(Lovinger and White, 1991) as well as G-protein inwardly rectifying (GIRK) and big 
potassium (BK) potassium channels  (Kobayashi et al., 1999; Chiou et al., 2002). 
 Ethanol alters neurotransmitter release, including glutamate, GABA, serotonin, 
and dopamine. A major focus has been on dopamine release in the mesolimbic pathway. 
The mesolimbic dopamine pathway consists of the dopamine cell bodies located in the 
ventral tegmental area (VTA) that project to the NAc. It is important to note that these 
dopamine neurons that classically have been implicated in motivation and drug 
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reinforcement, also have been shown to co-release glutamate in the NAc shell during 
optical stimulation (Stuber et al., 2010). Most drugs of abuse, including alcohol, increase 
dopamine release in the NAc when administered acutely. This increase in dopamine 
release is thought to contribute to drug reward and influence the addiction process 
through associative learning processes (Wise, 2004). Ethanol also regulates levels of 
neuroactive steroids (Morrow et al., 2001) that contribute to behavioral and physiological 
effects of ethanol. Considering the many sites of ethanol action and complex effects on 
neurophysiology it is challenging from a basic research perspective to unravel 
fundamental actions of ethanol and identify promising therapeutic targets for treating 
alcoholism.  
GABAA RECEPTORS 
  GABA is the primary inhibitory neurotransmitter in the CNS, and GABAA 
receptors are the primary receptor family. The GABAA receptor is a heteropentameric 
protein complex that forms a chloride permeable ion channel. Activation of GABAA 
receptors produces neuronal inhibition by increasing chloride flux into the cell reducing 
the membrane potential. This results in a decreased likelihood of an action potential, and 
therefore, inhibition of neurotransmission. To date, 19 subunits have been identified 
(Sarto-Jackson and Sieghart, 2008), and the subunit composition of a particular GABAA 
receptor determines its pharmacological profile. The GABAA receptors are the site of 
action for several different compounds besides GABA including benzodiazepines, 
barbiturates, anesthetics, neuroactive steroids, and picrotoxin. Several clinically relevant 
drugs, including anxiolytics, sedatives/hypnotics, and general anesthetics as well as 
endogenous neuroactive steroids, produce their effects via allosteric modulation of the 
 5 
GABAA receptor. GABAA receptors remain an attractive target for the development of 
new compounds for treating psychiatric disorders. 
ETHANOL EFFECTS ON GABAA RECEPTORS 
 Some of the effects of ethanol appear to be mediated via actions at the GABAA 
receptor. GABAA receptor agonists enhance and antagonists reduce ethanol effects 
(Lister and Linnoila, 1991). Electrophysiological studies have shown ethanol can affect 
neurotransmission through actions at synaptic GABAA receptors that produce phasic 
inhibition and consist of two , two β, and one , or at extrasynaptic GABAA receptors 
that produce tonic inhibition and consist of 4 or 6 and a  instead of  subunit. 
Extrasynaptic receptors respond to lower concentrations of ethanol, suggesting 
GABAergic effects at low doses of ethanol may be mediated via this population of 
receptors (Olsen et al., 2007). Ethanol’s effect on GABAA receptors is mainly thought to 
be due to enhancement of chloride current through the receptor, but there are a few 
reports of ethanol inhibition of GABAA receptors (Marszalec et al., 1994; Aguayo et al., 
2002). Evidence from transgenic animals suggests ethanol produces sedative/hypnotic 
effects largely via 1 subunit containing receptors (Kralic et al., 2003; June et al., 2007), 
but specific ethanol effects mediated by other subunits remain unclear. 
 It is not clear whether the effects of ethanol on GABAA receptors are produced 
via direct or indirect activation of the receptor. Although there is some evidence for direct 
activation of  subunit containing recombinant extrasynaptic receptors, these results are 
controversial (Santhakumar et al., 2007). There are many possibilities of indirect effects 
of ethanol on GABAA receptor function. One method of ethanol induced changes is by 
altering protein kinase A (PKA) or C (PKC), which can enhance GABAA receptor 
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function (Kumar et al., 2005; Choi et al., 2008). Ethanol can increase presynaptic GABA 
release (Roberto et al., 2003; Ariwodola and Weiner, 2004) in many but not all brain 
regions (Kelm et al., 2011). The GABA agonist taurine also can be increased by ethanol 
(De Witte et al., 1994), which at low levels can increase tonic inhibition (Jia et al., 2008). 
Ethanol also increases levels of potent GABAergic neuroactive steroids (Barbaccia et al., 
1999; Morrow et al., 1999; Khisti et al., 2003; O'Dell et al., 2004; Sanna et al., 2004; 
Boyd et al., 2010; Tokuda et al., 2011), which have similar pharmacologic effects as 
ethanol and are thought to contribute to some neurophysiological and behavioral effects 
of ethanol.  
NEUROACTIVE STEROIDS 
 Neuroactive steroids are endogenous neuromodulators that alter neuronal activity. 
This effect on neurotransmission is due to their actions at membrane bound receptors 
where they alter currents through ion channels, unlike the classic genomic steroid effects 
via regulation of gene expression. The term neurosteroid was coined over 30 years ago 
(Baulieu, 1981) to describe steroids which are synthesized de novo in the nervous system. 
These same steroids are also synthesized in the periphery where they are more generally 
referred to as neuroactive steroids. Levels of neuroactive steroids fluctuate depending on 
environmental factors like stress (Purdy et al., 1991b), biological factors including 
estrous/menstrual cycle (Purdy et al., 1990b) and pregnancy (Paul and Purdy, 1992), 
following drug administration (Marx et al., 2000; Porcu et al., 2004; Grobin et al., 2005; 
Pinna et al., 2006; Tokuda et al., 2010), and may be altered in some psychiatric disorders. 
Therefore, neuroactive steroids have garnered a lot of attention as potential therapeutic 
agents for multiple psychiatric disorders including depression (Uzunova et al., 1998), 
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anxiety disorders (Strohle et al., 2002), post-traumatic stress disorder (Rasmusson et al., 
2006), and schizophrenia (Marx et al., 2006). 
 Depending on the particular neuroactive steroid, the effects on neuronal activity 
can be excitatory or inhibitory. The sulfated derivatives of pregnenolone and 
dehydroepiandrosterone (DHEA) as well as the 3,5- and 3,5β-reduced metabolites of 
cortisol are considered excitatory neuroactive steroids due to their ability to enhance 
NMDA receptor activity (Farb and Gibbs, 1996), or inhibit GABAA receptor activity 
(Penland and Morrow, 2004). There are several inhibitory neuroactive steroids, often 
referred to as GABAergic neuroactive steroids. These include the 3,5- and 3,5β-
reduced metabolites are of progesterone, deoxycorticosterone, DHEA and testosterone. 
The most widely studied GABAergic neuroactive steroids are (3,5)-3-
hydroxypregnan-20-one (3α,5α-THP or allopregnanolone) and (3,5)-3,21-
dihydroxypregnan-20-one (3α,5α-THDOC), which are metabolites of progesterone and 
deoxycorticosterone, respectively. 3α,5α-THP and 3α,5α-THDOC are potent positive 
allosteric modulators of GABAA receptors, where they bind to two known neuroactive 
steroid transmembrane binding sites on  subunits (Hosie et al., 2006). One site on the  
subunit potentiates the receptor, while the other site located at the interface of  and β 
subunits activates the receptor directly at high concentrations. Therefore, they positively 
modulate synaptic and extrasynaptic receptors since all GABAA receptors likely contain 
 subunits. Furthermore, at high concentrations 3α,5α-THP and 3α,5α-THDOC can 
directly activate GABAA receptors in the absence of GABA (Ueno et al., 1997). 
Exogenous administration of 3α,5α-THP and 3α,5α-THDOC produces pharmacological 
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effects that are similar to ethanol including anxiolytic, sedative, anticonvulsant, and 
cognitive impairing effects (for review see, Morrow et al., 2001).  
NEUROACTIVE STEROID SYNTHESIS 
   Steroids are derived from cholesterol and are synthesized in the nervous system, 
adrenal glands, and gonads. Steroid synthesis begins in the mitochondria where the P450 
side chain cleavage (P450scc) enzyme converts cholesterol to pregnenolone (Fig. 1.1). 
Most steroidogenic cholesterol is derived from circulating lipoproteins, and there are 
multiple cholesterol transporters that move cholesterol from the outer mitochondrial 
membrane to the inner membrane where P450scc is located. Pregnenolone is then 
available to be converted to other steroid products. Steroid hormones are classified into 
five major classes: mineralocorticoids (aldosterone), glucocorticoids (corticosterone, 
cortisol), progestens (progesterone), androgens (testosterone, dihydrotestosterone) and 
estrogens (estradiol). Steroid synthesis is similar in most tissues and the steroid products 
depend on the biosynthetic enzymes present in that particular cell, which ultimately 
influences cell function. For instance, Leydig cells in the testis and ganulosa cells in the 
ovary predominantly produce testosterone and estrogens (Rommerts and Brinkman, 
1981; Garzo and Dorrington, 1984), respectively. This is due to the fact that Leydig and 
granulosa cells express enzymes responsible for the synthesis of testosterone and 
estrogens. The adrenal glands are important steroidogenic sites that regulate many aspects 
of physiology. The structure of the adrenal gland consists of a large outer cortex region, 
which encompasses the inner adrenal medulla region. The medulla produces the 
catecholamines epinephrine and norepinephrine, and receives information directly from 
the sympathetic nervous system via preganglionic fibers of the thoracic spinal cord. 
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Figure 1.1: Steroid biosynthetic pathway including synthetic enzymes. Inhibitory 
neuroactive steroids are shown in red and excitatory neuroactive steroids are shown in 
green.  
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 The adrenal cortex receives neuroendocrine hormones from the pituitary gland, 
which regulates function and steroid synthesis. Structurally, the adrenal cortex is divided 
into three layers (i.e. zones). The zones of the cortex are functionally distinct based on the 
steroids they produce, which is due to the biosynthetic enzymes present in each zone. The 
zona glomerulosa is the outermost layer and is responsible for production of the 
mineralocorticoid aldosterone, which regulates sodium concentrations and blood volume. 
The zona fasciculata is the middle zone and the site of glucocorticoid production, which 
are involved in glucose metabolism, stress responses, and regulation of other hormones. 
The innermost layer of the adrenal cortex is the zona reticularis where androgens are 
produced, which produce many sex-specific effects. The enzymes for neuroactive steroid 
synthesis are located in the zona fasciculate and zona reticularis (Compagnone et al., 
1995). 
 In the adrenal glands, neuroactive steroid synthesis is observed following 
hypothalamic-pituitary-adrenal (HPA) axis activation. Acute stress (Tsigos and Chrousos, 
2002) and some drug administrations, including alcohol (Boyd et al., 2010), activate the 
HPA axis. HPA activation increases release of corticotropin releasing factor (CRF) from 
the hypothalamus, which signals to neuroendocrine cells in the pituitary gland to release 
adrenocorticotropic hormone (ACTH). ACTH signals to the adrenal cortex to release 
GABAergic neuroactive steroids, neuroactive steroid precursors, and glucocorticoids. 
GABAergic neuroactive steroids can then provide negative feedback on the HPA by 
reducing CRF and ACTH release in rats (Owens et al., 1992; Patchev et al., 1994; 
Patchev et al., 1996). Recent evidence suggests that the GABAergic neuroactive steroid 
 11 
3α,5α-THDOC can also initiate the HPA stress response in C57BL/6J mice (Sarkar et al., 
2011).  
 The synthesis of neuroactive steroids in the adrenals can be due to hormonal 
peptide-induced increases of cyclic adenosine monophosphate (cAMP), increased 
availability of cholesterol, increased expression of the cholesterol transporter 
steroidogenic acute regulatory protein (StAR), and increased expression of P450 
hydroxylase and other steroidogenic enzymes. The transcription factor steroidogenic 
factor 1 (SF-1) regulates gene expression of many of the enzymes that increase 
steroidogenesis (Omura and Morohashi, 1995). Brain synthesis of neuroactive steroids is 
not well understood, but the prominent idea is that it is under the control of expression of 
biosynthetic enzymes (Baulieu, 1998; Compagnone and Mellon, 2000). Many of the 
neurosteroidogenic enzymes are expressed in the brain including StAR, P450scc, 5α-
reductase type I and II, 3α-hydroxysteroid dehydrogenase (3α-HSD), and 3β-
hydroxysteroid dehydrogenase (3β-HSD). Furthermore, the steroidogenic enzymes 
display brain regional specificity in their expression. In the case of the GABAergic 
neuroactive steroids 3α,5α-THP and 3α,5α-THDOC and their biosynthetic enzymes 5α-
reductase and 3α-HSD are located in the principal projecting neurons (Agis-Balboa et al., 
2006; Saalmann et al., 2007). Is has also been shown that environmental stress, which 
increases 3α,5α-THP in the cerebral cortex, also increases protein levels of 5α-reductase 
in the mPFC (Sanchez et al., 2009). Therefore, changes in brain expression of 
biosynthetic enzyme may underlie changes in these potent GABAergic neuroactive 
steroids. 
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EFFECTS OF ETHANOL ON GABAERGIC NEUROACTIVE STEROID 
SYNTHESIS 
 Ethanol activates the HPA axis (Boyd et al., 2010) causing the adrenal glands to 
increase steroids and steroid precursors into the peripheral bloodstream. In rats, ethanol 
doses of ~1.3g/kg and higher produce physiologically relevant increases of the 
GABAergic neuroactive steroids 3α,5α-THP and 3α,5α-THDOC in the blood plasma 
(Porcu et al., 2010). Ethanol also increases levels of 3α,5α-THP and 3α,5α-THDOC in 
the whole cerebral cortex (VanDoren et al., 2000), frontal cortex (O'Dell et al., 2004) and 
hippocampus (Barbaccia et al., 1999). In humans, 0.8g/kg ethanol administered orally 
fails to elevate 3α,5α-THP or 3α,5α-THDOC levels in the blood plasma of healthy men 
(Porcu et al., 2010). Due to ethical concerns, higher doses of ethanol cannot be 
administered to humans in the laboratory. However, previous studies have shown that 
adolescents requiring emergency services for acute alcohol intoxication displayed 
elevated levels of plasma 3α,5α-THP (Torres and Ortega, 2003, 2004). Therefore, similar 
to what is seen in rats, doses of ethanol higher than 0.8g/kg may increase levels of 3α,5α-
THP in humans.  
 Both 3α,5α-THP and 3α,5α-THDOC readily cross the blood brain barrier, and 
adrenalectomy prevents ethanol-induced elevations of 3α,5α-THP in the frontal cortex 
(O'Dell et al., 2004) and whole cerebral cortex (Khisti et al., 2003). Importantly, the 
administration of the immediate precursor of 3α,5α-THP, 5α-dihydroprogesterone (5α-
DHP), restores ethanol-induced increases of 3α,5α-THP in the cerebral cortex as well as 
corresponding effects of ethanol on loss of righting reflex following adrenalectomy 
(Khisti et al., 2003). This suggests that ethanol-induced increases of 3α,5α-THP in the 
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cerebral cortex are dependent on adrenal gland activation to provide 3α,5α-THP 
precursor. Ethanol-induced increases of 3α,5α-THP in the cerebral cortex are also 
dependent on de novo adrenal synthesis of the cholesterol transporter StAR (Boyd et al., 
2010). StAR transports cholesterol to the inner mitochondrial membrane where it is 
converted to pregnenolone by P450scc. Taken together, StAR synthesis in the adrenals 
may be necessary to provide precursor to the cerebral cortex where 3α,5α-THP is 
increased following ethanol. In vitro studies have shown that ethanol can increase levels 
of 3α,5α-THP in hippocampal slices (Sanna et al., 2004; Tokuda et al., 2011) in the 
absence of adrenal glands. It is not known in vivo, however, if ethanol can alter brain 
synthesis of 3α,5α-THP independent of the adrenal glands. 
 Studies investigating ethanol-induced changes of 3α,5α-THP in the brain have 
been limited to large brain regions like whole cerebral cortex or the hippocampus, which 
is highly enriched in 3α,5α-THP. Recently, our lab has been using immunohistochemistry 
(IHC) to measure levels of 3α,5α-THP in multiple brain regions that are implicated in 
alcohol use disorders. We have shown that ethanol (2g/kg) produces both increases and 
decreases of cellular 3α,5α-THP in the rat brain (Cook et al., 2013). Specifically, we have 
shown that ethanol increases cellular levels of 3α,5α-THP in the medial prefrontal cortex 
(mPFC), pyramidal cell layer of the CA1 hippocampus, polymorphic cell layer of the 
dentate gyrus (DG), bed nucleus of the stria terminalis, and paraventricular nucleus of the 
hypothalamus (PVN). Surprisingly, we also observed a decrease of cellular 3α,5α-THP in 
the NAc “shore” (core-shell border) and the central nucleus of the amygdala (CeA). 
Furthermore, there was no change in cellular levels of 3α,5α-THP in the granule cell 
layer of the DG, dorsomedial striatum, basolateral or lateral amygdala, or VTA. 
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Therefore, it appears that ethanol dynamically regulates cellular levels of 3α,5α-THP in 
the rat brain. 
GABAERGIC NEUROACTIVE STEROIDS CONTRIBUTE TO THE 
BEHAVIORAL AND NEUROPHYSIOLOGICAL EFFECTS OF ETHANOL 
 As mentioned above, ethanol administration in rats increases plasma, cerebral 
cortical, and hippocampal levels of the GABAergic neuroactive steroids 3α,5α-THP and 
3α,5α-THDOC. The ethanol-induced increases in GABAergic steroids are dose as well as 
time dependent and levels of steroids reach concentrations that are pharmacologically 
significant (VanDoren et al., 2000). A large body of evidence suggests the ethanol-
induced elevations of GABAergic neuroactive steroids contribute to many of the 
behavioral effects of ethanol in rats. For example, preventing GABAergic neuroactive 
steroid synthesis with the 5α-reductase inhibitor finasteride or performing adrenalectomy 
reduces the hypnotic (Khisti et al., 2003), anxiolytic-like, (Hirani et al., 2005), 
antidepressant-like (Hirani et al., 2002), and anticonvulsant (VanDoren et al., 2000) 
effects of ethanol. Importantly, in humans finasteride prevents some of the subjective 
effects of alcohol (Pierucci-Lagha et al., 2005). 
 GABAergic neuroactive steroids also contribute to the neurophysiological effects 
of ethanol. The neurophysiological effects of ethanol-induced increases of GABAergic 
neuroactive steroids have been best characterized in hippocampal pyramidal cells. 
Ethanol-induced increase of 3α,5α-THP in the hippocampus may contribute to ethanol-
induced impairment of memory and cognitive processes. In hippocampal pyramidal cells 
ethanol inhibits long-term potentiation (LTP), which is a type of synaptic plasticity 
thought to be a model of the physiological processes underlying learning and memory. 
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The same dose of ethanol that reduces LTP in CA1 pyramidal cells also increases 3α,5α-
THP immunoreactivity in these cells (Tokuda et al., 2011). Furthermore, inhibiting 
GABAergic steroid synthesis with finasteride prevents ethanol inhibition of LTP and 
increased 3α,5α-THP immunoreactivity. This suggests that ethanol inhibition of LTP may 
be mediated by 3α,5α-THP. Ethanol also increases 3α,5α-THP in isolated hippocampal 
tissue with concomitant increases in amplitude of GABAA receptor mediated spontaneous 
and evoked inhibitory postsynaptic currents in CA1 pyramidal cells, the latter of which 
was prevented by finasteride (Sanna et al., 2004). Effects of ethanol-induced increases of 
3α,5α-THP on pyramidal cell physiology are also observed in vivo. For example, 
systemic ethanol administration (1.5g/kg) reduces spontaneous firing of hippocampal 
pyramidal neurons in anesthetized rats, which is prevented by inhibiting GABAergic 
steroid synthesis with finasteride (Tokunaga et al., 2003b). Ethanol-induced increases of 
3α,5α-THP also modulate neurophysiology outside the hippocampus as well. Ethanol 
(1.5g/kg) reduces spontaneous firing of medial septal/diagonal band of Broca neurons, 
which is prevented by finasteride (VanDoren et al., 2000). Ethanol-induced changes in 
3α,5α-THP that contribute to behavioral effects of ethanol are likely due to effects of 
3α,5α-THP at GABAA receptors across many brain regions. Therefore, it will be 
important to examine the neurophysiological effects of ethanol-induced changes of 
3α,5α-THP in other brain regions. Since we recently showed that ethanol produces 
divergent effects on cellular levels of 3α,5α-THP in the rat brain (Cook et al., 2013), the 
neurophysiological effects of ethanol-induced changes in 3α,5α-THP levels are 
presumably functionally distinct depending on brain region. 
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NEUROACTIVE STEROIDS AND ETHANOL SELF-ADMINISTRATION 
 Systemic administration of endogenous and synthetic neuroactive steroids has 
been shown to reduce ethanol self-administration in rodents. The first steroid produced 
from cholesterol, pregnenolone, reduces operant ethanol self-administration in alcohol-
preferring (P) rats (Besheer et al., 2010a). In this same study, the authors showed that one 
of the effective doses of pregnenolone (50mg/kg) increased 3α,5α-THP levels in the 
cerebral cortex of P rats that had been trained to self-administer ethanol, but not in 
ethanol naive P rats. These data suggest that increased brain levels of 3α,5α-THP 
contribute to pregnenolone’s ability to reduce ethanol self-administration, and that a 
history of ethanol self-administration may produce adaptations in neuroactive steroid 
biosynthesis.  
 Systemic and intracerebroventricular (ICV) administration of 3α,5α-THP have 
been shown to produce biphasic effects on ethanol consumption using both homecage 
(Morrow et al., 2001; Ford et al., 2005; Ford et al., 2007) and operant self-administration 
of ethanol (Janak et al., 1998; Janak and Michael Gill, 2003). However, the effects of low 
dose systemic administration of 3α,5α-THP on ethanol consumption may depend on 
whether the animal is ethanol dependent. For example, a 5 mg/kg dose of 3α,5α-THP was 
shown to increase ethanol consumption in non-dependent P rats, but decreased 
consumption in dependent P rats (Morrow et al., 2001). Producing a reduction in ethanol 
consumption only in ethanol dependent animals is a desired outcome for a potential 
pharmacological treatment, since the treatment may be acting on neuroadaptations 
involved in ethanol dependence.  
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 The therapeutic value of exogenous 3α,5α-THP may be limited by rapid 
metabolism (Purdy et al., 1990a). Therefore, longer acting synthetic GABAergic 
neuroactive steroids such as ganaxolone may be more practical from a treatment 
standpoint. Ganaxolone has been shown to produce biphasic effects on operant ethanol 
self-administration in P rats, but the dose of ganaxolone that reduced ethanol responding 
also produced sedation (Besheer et al., 2010a). In mice, low (5 mg/kg) to mid (10mg/kg) 
dose ganaxolone has been shown to alter homecage ethanol consumption during a 24 
hour exposure similar to low dose 3α,5α-THP, but over an extended duration (Ramaker et 
al., 2011). Furthermore, a 10 mg/kg dose of ganaxolone decreased consumption using a 2 
hour limited access paradigm, but 5 and 10 mg/kg doses of ganaxolone did not 
significantly change operant ethanol self-administration (Ramaker et al., 2012). Higher 
doses of ganaxolone that may more consistently reduce ethanol drinking in mice hasn’t 
been tested, but there are concerns that 3α,5α-THP and ganaxolone may produce sedation 
at effective doses, thus, limiting therapeutic value. However, the synthetic GABAergic 
neuroactive steroid 3α,5β-20-oxo-pregnane-3-carboxylic acid (PCA) has been shown to 
dose dependently reduce operant ethanol self-administration in Wistar rats at doses that 
do not produce sedation (O'Dell et al., 2005).  
 The biphasic nature of 3α,5α-THP and ganaxolone modulation of ethanol 
consumption is not clear, but could result from low doses increasing the reinforcing effect 
of ethanol and high doses decreasing ethanol’s reinforcing effects. Previous studies have 
shown that 3α,5α-THP can be reinforcing. For example, rats were shown to preferentially 
consume a 3α,5α-THP solution over water in a two-bottle choice procedure (Sinnott et 
al., 2002). Multiple studies also have shown that 3α,5α-THP has ethanol-like 
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discriminative stimulus (i.e. 3α,5α-THP feels like ethanol) properties (Grant et al., 1996; 
Bowen et al., 1999; Hodge et al., 2001). In DBA/2J mice, systemic administration of 
3α,5α-THP has been shown to produce conditioned place preference (Finn et al., 1997). 
In rats, however, ICV administration of 3α,5α-THP has been shown to produce a 
conditioned place aversion (Beauchamp et al., 2000). Interestingly, a similar high dose of 
ICV 3α,5α-THP was shown to reduce dopamine release in the NAc and mPFC (Motzo et 
al., 1996). Furthermore, low dose ICV 3α,5α-THP administration increases dopamine 
release in the NAc (Rouge-Pont et al., 2002). Therefore, it is possible that 3α,5α-THP-
mediated biphasic changes in dopamine release may underlie the observed biphasic 
changes in ethanol reinforcement and consumption. 
 Increasing levels of GABAergic neuroactive steroids may have therapeutic value 
for treating individuals suffering from alcohol use disorders. The preclinical studies 
mentioned here have shown 3α,5α-THP reduces ethanol reinforcement and consumption. 
Furthermore, human alcoholics have reduced blood plasma levels of 3α,5α-THP during 
alcohol withdrawal (Romeo et al., 1996). Therefore, restoring levels of 3α,5α-THP during 
abstinence and withdrawal may be therapeutic. GABAergic neuroactive steroids also may 
alleviate withdrawal symptoms by reducing anxiety and CNS excitability, which are 
characteristic of alcohol withdrawal.  
RATIONALE FOR AIMS OF STUDIES 
 A large body of evidence has shown that ethanol produces pharmacologically 
relevant increases of 3α,5α-THP in the brain (for review see, Morrow, 2007). 
Specifically, it has been shown that ethanol increases 3α,5α-THP in the cerebral cortex 
and hippocampus. These increases of 3α,5α-THP are thought to contribute to the 
 19 
behavioral and neurophysiological effects of ethanol in rats. Importantly, 3α,5α-THP 
contributes to the subjective effects of alcohol in humans (Pierucci-Lagha et al., 2005) 
and levels of 3α,5α-THP are reduced in the blood of human alcoholics during 
withdrawal. Administration of 3α,5α-THP also can reduce ethanol reinforcement and 
consumption in rodent models of excessive alcohol consumption. Therefore, 
understanding how ethanol regulates 3α,5α-THP levels in the brain is important for 
understanding ethanol action and developing new treatments for alcohol use disorders. 
Although these studies are focused on ethanol-related effects, results and approaches 
from these experiments may be applied to other neuropsychiatric disorders where 
neuroactive steroids may be altered and/or changing levels of neuroactive steroids may be 
therapeutic.  
AIM I RATIONALE 
 It has been known for more than 10 years that ethanol increases levels of 3α,5α-
THP in the blood plasma, whole cerebral cortex, and whole hippocampus of rats 
(Barbaccia et al., 1999; VanDoren et al., 2000). Elevations of 3α,5α-THP contribute to 
the pharmacological effects of ethanol, presumably via actions at GABAA receptors 
across many brain regions. However, due to limitations in available 3α,5α-THP assays, it 
is not known if ethanol alters levels of 3α,5α-THP in other brain regions. Therefore, we 
optimized an immunohistochemical assay for measuring cellular levels of 3α,5α-THP in 
the rat brain. Preliminary results investigating ethanol-induced changes in cellular 3α,5α-
THP levels showed that ethanol produced increases, decreases, or no change in 3α,5α-
THP dependent on the brain region or cellular population evaluated. These results are 
intriguing and suggest that ethanol alters local synthesis and/or metabolism of 3α,5α-THP 
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in the brain. Previous in vivo results have shown that ethanol-induced increases of 3α,5α-
THP in the cerebral cortex are dependent on adrenal gland activation since adrenalectomy 
prevents 3α,5α-THP elevations. However, there is in vitro evidence for local brain 
synthesis of 3α,5α-THP in hippocampal slices, in the absence of adrenal influence. 
Therefore, aim I focused on examining the effects of ethanol on cellular 3α,5α-THP 
expression in several brain regions implicated in alcohol use disorders, and to determine 
the role of the adrenal glands in these effects.  
AIM II RATIONALE 
 Systemic administration of the endogenous neuroactive steroids pregnenolone and 
3α,5α-THP reduces ethanol reinforcement and consumption in rodents. Systemic 3α,5α-
THP administration also reduces escalation of cocaine self-administration (Aker et al., 
2010). It is not known where in the brain neuroactive steroids act to reduce drug self-
administration, but ICV administration of 3α,5α-THP produces biphasic effects on 
ethanol consumption as well as dopamine release in mesolimbic circuitry. Therefore, we 
hypothesized that increased 3α,5α-THP in mesolimbic regions would reduce ethanol self-
administration. The therapeutic potential of 3α,5α-THP, however, may be limited by 
rapid metabolism as well as nonspecific effects such as sedation. Therefore, we 
developed a recombinant adeno-associated serotype 2 (rAAV2) vector to overexpress the 
P450scc enzyme and drive neurosteroidogenesis locally within neurons of the NAc or 
VTA of P rats self-administering ethanol. The AAV2 vector was chosen because it 
selectively infects neurons, produces minimal immune response, and allows us to 
examine long-term effects on ethanol self-administration. Transduction of P450scc will 
only be effective in cells that contain other requisite biosynthetic enzymes for production 
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of the neuroactive steroids. The selectively bred P rat fulfills the requirement of an 
animal model of alcoholism (Lester and Freed, 1973) since they readily consume ethanol 
in amounts that produce physiologically significant blood alcohol concentration, maintain 
ethanol preference in the presence of palatable solutions, and develop ethanol tolerance 
and dependence. We predicted that behavioral effects of increasing neurosteroidogenesis 
with the rAAV2-P450scc vector would be associated with increased 3α,5α-THP due to its 
potency at GABAA receptors, involvement in ethanol action, and ability to modulate 
ethanol self-administration. 
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 EFFECTS OF ETHANOL ON 3,5-THP CHAPTER 2.
IMMUNOHISTOCHEMISTRY IN THE RAT BRAIN 
 
 
INTRODUCTION 
Neuroactive steroids are endogenous neuromodulators capable of altering 
neuronal activity. Synthesis of neuroactive steroids occurs in the adrenal glands, gonads, 
and de novo in the brain. The 5α-reduced pregnane steroids, (3,5)-3-hydroxypregnan-
20-one (3α,5α-THP or allopregnanolone) and (3,5)-3,21-dihydroxypregnan-20-one 
(3α,5α-THDOC), are positive allosteric modulators of γ-aminobutyric acid type A 
(GABAA) receptors. GABAA receptors are the primary inhibitory receptor family in the 
brain and mediate many of the behavioral effects of ethanol. Both 3α,5α-THP and 3α,5α-
THDOC enhance neuronal inhibition at a known binding site on GABAA receptor α-
subunits (Hosie et al., 2006), and have corresponding behavioral effects similar to 
ethanol. These GABAergic neuroactive steroids are very potent positive modulators of 
GABAA  receptors, which produce pharmacologically relevant effects at nanomolar 
concentrations (Morrow et al., 1987).  
A large body of evidence suggests increased levels of 3α,5α-THP and 3α,5α-
THDOC following ethanol administration contribute to both electrophysiological and 
behavioral effects of ethanol in rodents. In rats, ethanol activates the hypothalamic-
pituitary-adrenal (HPA) axis (Boyd et al., 2010) leading to physiologically significant 
23 
 
increases of 3α,5α-THP and 3α,5α-THDOC in the blood plasma, cerebral cortex, and 
hippocampus (Barbaccia et al., 1999; VanDoren et al., 2000; Porcu et al., 2009). 
Adrenalectomy or inhibition of 5α-reduced steroid synthesis with the 5α-reductase (5α-R) 
inhibitor finasteride reduces some of the behavioral effects of ethanol, including the 
hypnotic (Khisti et al., 2003), anxiolytic-like (Hirani et al., 2005), anticonvulsant 
(VanDoren et al., 2000), and anti-depressant-like (Hirani et al., 2002) effects in rats. 
Furthermore, finasteride reduces some of the subjective effects of alcohol in healthy men 
(Pierucci-Lagha et al., 2005). Finasteride also blocks ethanol inhibition of neuron firing 
in the medial septum (VanDoren et al., 2000), hippocampus (Tokunaga et al., 2003b), 
hippocampal slice (Sanna et al., 2004), and long-term potentiation (LTP) in the 
hippocampal slice preparation (Tokuda et al., 2011). Taken together, these findings 
suggest ethanol-induced elevations of 3α,5α-THP and 3α,5α-THDOC contribute to many 
of the physiological and behavioral effects of ethanol. However, outside of the cerebral 
cortex and hippocampus, it is not known if ethanol increases levels of 3α,5α-THP in other 
brain regions that contribute to ethanol’s myriad of pharmacological effects.  
GABAergic neuroactive steroids are involved in stress responses; therefore, 
steroid concentrations may be altered in stress related neurocircuitry following ethanol 
administration. GABAergic neuroactive steroids are increased in the plasma and cerebral 
cortex following environmental stress (Purdy et al., 1991a; Barbaccia, 1996), including 
ethanol administration. GABAergic neuroactive steroids contribute to negative feedback 
on the HPA axis at the level of the hypothalamus in rats (Owens et al., 1992; Patchev et 
al., 1994; Patchev et al., 1996), but not in C57BL/6J mice (Sarkar et al., 2011). 
Furthermore, recent evidence in C57BL/6J mice suggests GABAergic neuroactive 
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steroids are involved in initiation of the stress response (Sarkar et al., 2011). In the 
current study, we investigated ethanol-induced changes of 3α,5α-THP in the 
paraventricular nucleus (PVN) of the hypothalamus, the bed nucleus of the stria 
terminalis (BNST), and amygdala due to the involvement of these regions in stress, 
emotion, and ethanol responses (Armario, 2010; Cui et al., 2012; Koob, 2013).  
Ethanol and 3α,5α-THP both impair learning and memory performance in a 
similar manner (Matthews et al., 2002), which may be due to modulation of activity of 
specific cellular populations in the hippocampus (Matthews et al., 2002; Tokunaga et al., 
2003b; Tokuda et al., 2011). In vitro, ethanol increases 3α,5α-THP immunoreactivity in 
hippocampal pyramidal cells (Tokuda et al., 2011), and finasteride prevents ethanol’s 
inhibitory effect on these cells in anesthetized rats (Tokunaga et al., 2003b). Therefore, 
we examined the cellular layer specificity of ethanol effects on 3α,5α-THP levels in the 
hippocampal formation. 
Systemic and intracerebroventricular administration of exogenous 3α,5α-THP or 
systemic administration of the longer acting 3α,5α-THP analogue, ganaxolone, alter 
ethanol consumption in rodents. Both 3α,5α-THP and ganaxolone have been shown to 
produce biphasic effects on ethanol consumption, with low doses increasing consumption 
and high doses decreasing consumption (Janak et al., 1998; Morrow et al., 2001; Ford et 
al., 2005; Ford et al., 2007; Besheer et al., 2010a). The mechanisms by which 3α,5α-THP 
affects ethanol consumption are not clear, but these effects could be due to modulation of 
dopamine release in mesocorticolimbic circuitry (Motzo et al., 1996; Rouge-Pont et al., 
2002). Therefore, we examined the effects of ethanol on 3α,5α-THP immunoreactivity in 
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the ventral tegmental area (VTA), nucleus accumbens (NAc), striatum, and medial 
prefrontal cortex (mPFC). 
Previous studies measuring ethanol-induced changes of 3α,5α-THP in the brain have 
used radioimmunoassay (RIA) or gas chromatography-mass spectroscopy (GC-MS), 
which lack the sensitivity to determine levels in discrete cell layers or brain regions with 
low levels of 3α,5α-THP.  Although ethanol increases levels of 3α,5α-THP in the cerebral 
cortex and hippocampus, it is unknown whether ethanol alters levels of 3α,5α-THP in 
other brain regions. Immunohistochemistry (IHC) using an anti-3α,5α-THP primary 
antibody was used to examine ethanol-induced changes in cellular 3α,5α-THP levels. 
This technique has been used to determine the cellular distribution of 3α,5α-THP in the 
rat brain (Saalmann et al., 2007) and displays the sensitivity to detect changes in 
immunoreactivity that are associated with corresponding changes in electrophysiological 
measurements (Saalmann et al., 2006; Tokuda et al., 2011). We examined ethanol-
induced changes in cellular 3α,5α-THP expression across multiple brain regions that are 
implicated in alcohol use disorders. This approach provides brain region specificity of 
neuroactive steroid measurements that has not previously been reported following ethanol 
administration, and may reveal novel mechanisms of ethanol action.  
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MATERIALS AND METHODS 
Subjects 
Adult male Wistar rats (~250 g/7-8 per group) were purchased from Harlan 
Laboratories (Indianapolis, IN, USA). The animals were housed in Plexiglass cages (2 to 
4 per cage) with food and water available ad libitum. The colony room was maintained 
on a normal 12 hr light-dark cycle (light onset at 0700 hr) and at a constant temperature 
of 22 ± 2 C and relative humitity of 65%. The animals were allowed 1 week to acclimate 
to the colony room. Following acclimation, the animals were habituated to handling and 
intraperitoneal (i.p.) saline injections for 5 days. Experiments were conducted between 
0800 and 1300 hr to minimize potential circadian fluctuation in neuroactive steroid 
levels. 
Ethanol (2g/kg, 20% v/v in saline) or saline was administered by i.p. injection 60 
minutes before transcardial perfusion. Animal care and handling procedures followed 
National Institutes of Health Guidelines under University of North Carolina at Chapel 
Hill Institutional Animal Care and Use Committee approved protocols.    
Antibody specificity tests 
The specificity of the affinity purified 3α,5α-THP antibody was measured by 
RIA. Standards of 3α,5α-THP, 3α,5α-THDOC, (3α,5β)-3-hydroxypregnan-20-one 
(3α,5β-THP), pregnenolone, progesterone and (3α)-3-hydroxy-4-pregnen-20-one (3α-HP) 
were diluted in 95% ethanol at an initial concentration of 0.1 mg/ml. The compounds 
were serially diluted to a range of 0.0049 - 40.0 ng/ml, no more than 24 hours before the 
assay. RIAs were repeated three times for each compound, following previously 
described methods (Janis et al., 1998). Briefly, 5 µl of each concentration of the tested 
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compounds were mixed with 10,000 CPM of [
3
H]-3α,5α-THP and a 1:500 dilution of the 
affinity purified 3α,5α-THP antiserum. Unbound [3H]- 3α,5α-THP was removed by 
centrifugation after adding dextran-coated charcoal. The supernatant was mixed with 
Ecoscint H (National Diagnostics) and [
3
H]-3α,5α-THP was measured in a scintillation 
counter. The resulting curves were analyzed using a one-site competition model (Prism, 
GraphPad Software, La Jolla, CA, USA) for EC50 values. We observed cross reactivity 
with 3α, hydroxy-4-pregnen-20-one (3α-HP; 41±0.14%), (3α,5β)-3-hydroxypregnan-20-
one (3α,5β-THP; 22±0.43%), progesterone (14±1.95%), 3α,5α-THDOC (11±0.29%), and 
pregnenolone (9±1.61%) as expected from previous reports using a different antibody 
preparation (Janis et al., 1998; VanDoren et al., 2000; Khisti et al., 2003; Boyd et al., 
2010).  
Immunohistochemistry 
 Fifty minutes after 2g/kg ethanol or saline injection the animals were anesthetized 
with pentobarbital (100mg/kg, i.p.; Professional Compounding Centers of America, 
Houston, TX, USA) and transcardially perfused approximately 1hr following ethanol or 
saline injection with phosphate buffered saline (PBS) followed by 4% paraformaldehyde. 
Tissue was post-fixed in 4% paraformaldehyde for 24hr at 4°C, sectioned coronally on a 
vibrating microtome at 40μm, and stored at -30°C until further processing.  
 Immunohistochemical assays were performed using a procedure modified from 
(Saalmann et al., 2007). No detergents or organic solvents were used to prevent the 
possibility of neuroactive steroid leeching. Free floating brain sections (3-4 
sections/animal/brain region) were rinsed in PBS, followed by incubation in 1% 
hydrogen peroxide to block endogenous peroxidase activity, and then blocked using 10% 
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rabbit serum in PBS. Next, the tissue was incubated in sheep affinity purified anti-3α,5α-
THP antiserum (targeted against 3α,5α-THP carboxymethyl ether coupled to bovine 
serum albumin; purchased from Dr. R.H. Purdy) at a 1:2500 dilution for 48 hr at 4°C. 
Following rinsing in PBS, tissue was incubated in a rabbit anti-sheep biotinylated 
secondary antibody (1:200; Vector laboratories, Burlingame, CA, USA) for 1 hr. After 
rinsing in PBS, avidin biotin amplification was performed with a Vectastain Elite ABC 
kit (Vector Laboratories, Burlingame, CA, USA) and immunoreactivity was visualized 
with 3,3’-diaminobenzidine ( DAB; Polysciences, Inc., Warrington, PA, USA and Sigma-
Aldrich, St. Louis, MO, USA) using the manufacturers’ recommended procedures.   
Immunohistochemical analysis 
Immunoreactivity was visualized using an Olympus CX41 light microscope 
(Olympus America, Center Valley, PA, USA) and images were captured with a digital 
camera (Regita model, QImaging, Burnaby, BC). Image analysis software (Bioquant Life 
Sciences version 8.00.20; Bioquant Life Sciences, Nashville, TN, USA) that utilizes 
linear integrated optical density was used for comparing relative changes in 
immunoreactivity between groups. The microscope, camera, and software were 
background corrected and normalized to preset light levels to ensure fidelity of data 
acquisition. Immunoreactive positive pixel count measurements were calculated from a 
circumscribed field (e.g., brain region), divided by the area of the region in square 
millimeters, and expressed as positive pixels/mm
2
. Data were acquired from 3-4 
sections/animal/brain region, and data were averaged within a brain region for an 
individual animal to obtain one value per subject. Inter-rater reliability was determined 
by calculating the intraclass-correlation coefficient for two raters blind to the 
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experimental conditions. The polymorph dentate gyrus (DG), NAc, and mPFC were 
chosen randomly from 6 brain regions for analysis and values of r = 0.85 (p < 0.001), r = 
0.78 (p < 0.01), and r = 0.77 (p < 0.005) were obtained, respectively. Intraclass-
correlation coefficient was calculated using MATLAB (MathWorks, Natick, MA, USA). 
Immunoreactivity was measured separately for each brain region and statistically 
analyzed using Student’s t-test (Prism, GraphPad Software, La Jolla, CA, USA) to 
compare the ethanol versus saline group within each brain region. 
Brain region analyses were performed using histological coordinates as follows: 
mPFC (+3.00 to +2.20 AP), amygdala [central nucleus (CeA); lateral amygdala; 
basolateral amygdala; -2.56 to -3.14 AP], NAc (+ 1.70 to + 1.00 AP), dorsomedial 
striatum [DMS (+1.70 to + 1.00 AP)], VTA (-5.20 to -6.04 AP), hippocampus [pyramidal 
cell layer of CA1 (-2.56 to -3.14 AP), polymorph (-2.56 to -3.14 AP) and granule (-2.56 
to -3.14 AP) cell layers of the DG, BNST (-0.26 to -0.40 AP), hypothalamus [PVN, (-
1.60 to -2.12 AP)]. All analyses were based on coordinates relative to bregma in the Rat 
Brain Atlas (Paxinos and Watson, 1998).  
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RESULTS 
Ethanol-induced increases of cellular 3α,5α-THP 
Previous studies using RIAs have shown ethanol-induced increases in 3α,5α-THP 
levels in the rat cortex and hippocampus (Barbaccia et al., 1999; VanDoren et al., 2000). 
Therefore, we first examined these regions to determine if the elevations displayed sub-
region or cellular layer specificity. Ethanol administration (2g/kg, i.p.) increased 3α,5α-
THP immunoreactivity in the mPFC [24±6%; t(13)=2.996, p < 0.01]. The effects of 
ethanol appear uniform across the cortical cell layers (Fig. 2.1A).  In hippocampus, 
ethanol increased 3α,5α-THP immunoreactivity in the pyramidal cells of the CA1 region 
[32±12%; t(14)=2.401, p < 0.05] (Fig. 2.1B), and the polymorph cell layer of the DG 
[52±5%; t(14)=5.288, p < 0.001] (Fig. 2.2A), but had no effect on cellular 3α,5α-THP in 
the granule cell layer of the DG (Fig. 2.2B), indicating cellular layer specificity in the 
response to ethanol.  
 Ethanol also increased 3α,5α-THP immunoreactivity in brain regions involved in 
stress responses. We examined ethanol effects on cellular 3α,5α-THP levels in the PVN 
due to its role in modulating HPA axis activity. We also investigated ethanol’s effects on 
cellular 3α,5α-THP in the BNST due to its role as an interface between stress and reward 
circuitry and involvement in ethanol responses (Cui et al., 2012). Ethanol administration 
(2g/kg, i.p.) increased 3α,5α-THP immunoreactivity in both the PVN [36±6%; 
t(14)=3.406, p < 0.01] (Fig. 2.3A) and BNST [44±15%; t(13)=2.346, p < 0.05] (Fig. 
2.3B). 
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Ethanol-induced decreases of cellular 3α,5α-THP  in regions associated with ethanol 
reinforcement and consumption 
 Multiple studies suggest that 3α,5α-THP alters ethanol consumption (Morrow et 
al., 2001; Ford et al., 2005; Ford et al., 2007) and reinforcement (Janak et al., 1998; Janak 
and Michael Gill, 2003), so we examined the effects of ethanol administration (2g/kg, 
i.p.) in regions that are known to contribute to these phenomena. Ethanol administration 
did not alter 3α,5α-THP immunoreactivity in the VTA. Interestingly, ethanol 
administration decreased 3α,5α-THP immunoreactivity in the NAc [-22±5%; 
t(12)=3.214, p < 0.01] (Fig. 2.4A) but had no effect on 3α,5α-THP in the DMS (Fig. 2.4 
B) or VTA (Fig. 2.4C). The ethanol-induced reduction of 3α,5α-THP in the NAc was 
only detected in the NAc “shore” (core-shell border), as no changes in 3α,5α-THP were 
found in the NAc core or the NAc shell (data not shown), indicating sub-region 
specificity of ethanol effects on 3α,5α-THP levels in the ventral striatum. Ethanol 
administration reduced 3α,5α-THP immunoreactivity in the CeA [-21±3%; t(14)=2.508, p 
< 0.05] (Fig. 2.5A), but there was no change in 3α,5α-THP in the lateral (Fig. 2.5B) or 
basolateral amygdala (Fig. 2.5C). Therefore, ethanol produces sub-region specific effects 
on 3α,5α-THP in amygdala regions as well. 
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DISCUSSION 
The goal of the present study was to use IHC to examine ethanol-induced changes 
in cellular 3α,5α-THP expression in multiple brain regions implicated in alcohol use 
disorders. Our findings support previous evidence that ethanol increases 3α,5α-THP 
concentrations in the rat cerebral cortex and hippocampus using RIA or GC-MS. We 
extend previous findings by showing that ethanol increases cellular 3α,5α-THP in the 
mPFC, CA1 pyramidal cell layer, and polymorph cell layer of the DG but not in granule 
cells of the DG. Therefore, ethanol-induced increases of cellular 3α,5α-THP in the 
hippocampus are isolated to specific cellular populations. We also show that ethanol 
increases cellular 3α,5α-THP levels in the BNST and the PVN of the hypothalamus. 
Interestingly, acute ethanol administration reduced cellular 3α,5α-THP levels in the NAc 
“shore” (core-shell border) and the CeA. To our knowledge, this is the first example of 
acute ethanol reducing 3α,5α-THP levels in the rat brain or periphery. We also 
determined that ethanol does not alter 3α,5α-THP levels in the VTA, DMS, or the lateral 
or basolateral amygdala. Therefore, ethanol produces divergent brain region and cellular 
layer specific changes in 3α,5α-THP concentrations. 
The immunohistochemical technique used in the present study provides brain 
region and cell layer specificity of ethanol-induced changes in 3α,5α-THP. A similar IHC 
assay was used to demonstrate that 3α,5α-THP is located primarily in GABAergic and 
glutamatergic projecting principle neurons, but not in interneurons or glia (Saalmann et 
al., 2007). The present results indicate similar relative intensity of basal staining across 
brain, with strong labeling of cortical and hippocampal cell layers as well as the striatum. 
There are some important differences between measurements of 3α,5α-THP with IHC 
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compared to RIA measurements. IHC measures cellular levels of 3α,5α-THP but RIA 
measures absolute levels of neuroactive steroids. Therefore, if there are significant pools 
of extraneuronal 3α,5α-THP present in brain tissue, one might predict IHC measurements 
would differ from results obtained by RIA. Our current IHC results in the mPFC, CA1 
pyramidal, and DG polymorph cell layer show that ethanol increased relative 3α,5α-THP 
immunoreactivity by 24±6%, 32±12%, and  52±5% , respectively. However, RIA studies 
measuring ethanol-induced increases of 3α,5α-THP in whole cerebral cortex and 
hippocampus have found larger increases of 3α,5α-THP using similar doses. For 
example, increases of 5-17 fold (Barbaccia et al., 1999), ~3 fold (VanDoren et al., 2000; 
Khisti et al., 2004), and ~2 fold (Boyd et al., 2010) have been observed in the cerebral 
cortex, while studies examining whole hippocampus have found 4-11 (Barbaccia et al., 
1999) and ~6 fold (Khisti et al., 2004) increases in 3α,5α-THP concentrations. The 
discrepancies in magnitude of ethanol-induced increases of 3α,5α-THP could be due to 
relatively small increases of 3α,5α-THP in the mPFC when compared to the whole 
cortex, and similarly, small relative increases of 3α,5α-THP in the CA1 pyramidal cells 
and the polymorph cell layer of the DG compared to whole hippocampus. It is important 
to note we are using an affinity purified 3α,5α-THP antiserum that appears to be more 
specific in detecting 3α,5α-THP. The only other study examining ethanol’s effects on 
3α,5α-THP using the affinity purified 3α,5α-THP antiserum used IHC with 
immunofluorescent detection and found over a 200% increase in fluorescent intensity in 
CA1 pyramidal cells (Tokuda et al., 2011) compared to a 32±12% increase in 
immunoreactivity in the present study using DAB detection. Although ethanol increased 
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3α,5α-THP using both fluorescent and DAB visualization, the magnitude of 3α,5α-THP 
changes may differ due to differences in immunohistochemical methodology. 
The 3α,5α-THP antisera used in the present study was found to cross-react with 
3α-HP (41±0.14%) and 3α,5β-THP (22±0.43%). This is not a major limitation since both 
of these steroids have similar GABAergic activities as 3α,5α-THP. Furthermore, there is 
no evidence that 3α-HP (Griffin and Mellon, 2001) or 3α,5β-THP are present in the brain 
in appreciable concentrations. In addition, ethanol does not elevate 3α,5β-THP levels in 
rat plasma (Porcu et al., 2010). Therefore, 3α,5α-THP is the most likely endogenous 
antigen immunolabelled using this approach. A potential limitation of the study is that 
only one dose of ethanol was examined. In the cerebral cortex, a threshold dose of 
ethanol (1.3-1.5 g/kg) is required to produce an increase of 3α,5α-THP and increasingly 
higher doses produce less of an increase of 3α,5α-THP (VanDoren et al., 2000; Boyd et 
al., 2010). However, since only one dose was used it is not known if a similar threshold 
dose is needed to produce increases or decreases of 3α,5α-THP in the cortical and 
subcortical brain regions examined in the present study. Similarly, it is not clear if 
ethanol produces a biphasic effect on 3α,5α-THP levels in these brain regions. 
The diverse effects of ethanol administration on cellular 3α,5α-THP levels 
suggest that ethanol may alter local synthesis and/or metabolism of 3α,5α-THP in the rat 
brain. These results suggest ethanol-induced changes of cellular 3α,5α-THP in the brain 
are not due exclusively to adrenal gland derived elevations of neuroactive steroids or 
steroid precursors, which would be expected to increase 3α,5α-THP throughout the brain. 
However, we observed no change in 3α,5α-THP levels after acute ethanol administration 
in the granule cell layer of the DG and the DMS, which both display dense labeling of 
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3α,5α-THP (Saalmann et al., 2007) as well as the biosynthetic enzymes 5α-R and 3α-
hydroxysteroid dehydrogenase (3α-HSD) needed for 3α,5α-THP synthesis (Agis-Balboa 
et al., 2006). Furthermore, there was a reduction of cellular 3α,5α-THP in the NAc and 
the CeA. Based on these findings our data suggest there are unknown mechanisms 
contributing to ethanol’s effects on 3α,5α-THP concentrations. In the cerebral cortex, 
ethanol-induced elevations of 3α,5α-THP are dependent on the pituitary-adrenal axis 
(Khisti et al., 2003; O'Dell et al., 2004; Boyd et al., 2010). In vitro, however, there is 
evidence for ethanol-induced brain synthesis of 3α,5α-THP in hippocampal slices (Sanna 
et al., 2004; Tokuda et al., 2011). Thus, it is not known if ethanol alters brain synthesis of 
3α,5α-THP in vivo independent of  circulating steroids. Therefore, it will be important to 
determine the role of circulating steroids in the current observations, which may provide 
insight into this important question. 
The most striking finding in the present study is that ethanol produces brain 
region and cellular layer specific changes in 3α,5α-THP concentrations. These data 
suggest ethanol alters local synthesis of 3α,5α-THP in the rat brain. A possible 
mechanism that may explain these findings is ethanol may change local expression and/or 
activity of steroidogenic enzymes. Steroidogenesis is initiated by cholesterol transport to 
cytochrome P450 side chain cleavage (P450scc), resulting in conversion of cholesterol to 
pregnenolone. Previous work from our laboratory has shown that de novo adrenal 
synthesis of the cholesterol transporter, steroidogenic acute regulatory protein (StAR), is 
necessary for ethanol-induced increases of 3α,5α-THP in the cerebral cortex (Boyd et al., 
2010). Acute ethanol administration increases StAR and P450scc mRNA in the rat frontal 
cortex and hypothalamus, and StAR mRNA is also increased in the hippocampus (Kim et 
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al., 2003). The synthesis of 3α,5α-THP from progesterone is accomplished by the 
sequential actions of 5α-R and 3α-HSD. Acute ethanol administration increases 5α-R 
type 1 (5α-RI) and 3α-HSD mRNA in the frontal cortex and 3α-HSD mRNA in the 
hypothalamus, but no change in transcript expression of either enzyme were detected in 
the hippocampus (Kim et al., 2003). Unfortunately, there are no data examining the 
effects of acute ethanol on expression of these enzymes in the NAc or CeA where we 
observed reductions in 3α,5α-THP. However, chronic intermittent ethanol administration 
reduces 3α,5α-THP levels in the hippocampus, which is associated with concurrent 
decreases in 5α-RI and 3α-HSD mRNA expression (Cagetti et al., 2004). Taken together, 
ethanol-induced changes in steroidogenic enzyme expression may underlie the divergent 
changes in 3α,5α-THP levels observed in the rat brain. Additionally, ethanol may directly 
or indirectly change the activity of steroidogenic enzymes, which could alter steroid 
concentrations. Ultimately, ethanol may alter the expression and/or activity of enzymes 
involved in steroid synthesis and metabolism, resulting in local changes in neurosteroid 
levels that are dependent on which enzymes are expressed in a particular cell. 
Another possible explanation for the reduction in cellular 3α,5α-THP levels 
observed in the NAc and CeA is extracellular redistribution of 3α,5α-THP. Neuroactive 
steroids have been proposed to act on membrane bound receptors by a paracrine or 
autocrine mechanism (Herd et al., 2007), or by lateral diffusion through the cell 
membrane to access transmembrane neuroactive steroid binding sites on GABAA 
receptors (Akk et al., 2007). Although controversial, we cannot rule out the possibility 
that ethanol leads to a “release” or redistribution of 3α,5α-THP into the extracellular 
space, perhaps in a brain region specific manner.  
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Significance of ethanol-induced changes in cellular expression of 3α,5α-THP 
Evidence suggests ethanol-induced increases of 3α,5α-THP contribute to the 
behavioral effects of ethanol in rodents and some of the subjective effects of alcohol in 
humans. Contribution of 3α,5α-THP to the pharmacological effects of ethanol is likely 
due to potentiation of GABAA receptors across multiple brain regions. The localization of 
3α,5α-THP and the biosynthetic enzymes 5α-R and 3α-HSD in principle output neurons 
suggests a major role of 3α,5α-THP may be to modulate neural circuitry (Agis-Balboa et 
al., 2006; Saalmann et al., 2007). The neurophysiological effects of 3α,5α-THP have been 
best characterized in hippocampal pyramidal cells. In vivo, ethanol (1.5g/kg) reduces 
spontaneous activity of hippocampal pyramidal cells in anesthetized rats, which is 
prevented by finasteride pre-administration (Tokunaga et al., 2003b). In vitro, ethanol 
(50, 100 mM) increases 3α,5α-THP in isolated hippocampal tissue and amplitude of 
GABAA receptor mediated spontaneous and evoked IPSCs in CA1 pyramidal cells 
(Sanna et al., 2004), the latter of which is prevented by pretreatment with finasteride. 
Ethanol (60 mM) also inhibits LTP in CA1 pyramidal cells, with concomitant increases 
in 3α,5α-THP immunostaining (Tokuda et al., 2011). Furthermore, pretreatment with 
finasteride blocks ethanol’s inhibition on LTP, suggesting that ethanol’s ability to inhibit 
LTP is mediated by 3α,5α-THP. In the present study, ethanol increased 3α,5α-THP in the 
polymorphic cell layer but not the granule cell layer of the DG. Although we did not 
distinguish which polymorphic cells exhibit increased 3α,5α-THP, the most prominent 
cell type in this layer is the mossy cell. Mossy cells in the polymorphic layer project to 
the molecular and granule cell layers of the DG (Amaral et al., 2007), the latter of which 
constitutes the only projection from the DG to the hippocampus. Considering the major 
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role the hippocampus and DG play in learning and memory, 3α,5α-THP induction by 
ethanol may contribute to ethanol’s effects on memory and cognition. 
Ethanol-induced changes in brain concentrations of 3α,5α-THP may also 
modulate neuronal activity in other brain regions examined in the present study. In vivo 
evidence suggests ethanol-induced increases of 3α,5α-THP modulate neuronal activity 
outside of the hippocampus as well. For example, finasteride prevents ethanol (1.5g/kg) 
inhibition of spontaneous firing of medial septal/diagonal band of Broca neurons 
(VanDoren et al., 2000). In addition to hippocampal pyramidal cells, we observed 
increases of cellular 3α,5α-THP in the polymorph DG, mPFC, BNST, and PVN of the 
hypothalamus. The physiological consequences of 3α,5α-THP increases may alter 
neuronal activity and synaptic plasticity in these regions and related circuitry. Clearly, 
studies are needed to examine how increases of 3α,5α-THP in these brain regions may 
contribute to the physiological and behavioral effects of ethanol. 
Ethanol-induced reductions of cellular 3α,5α-THP were observed in the NAc and 
CeA. These observations are particularly interesting because these two brain regions are 
strongly associated with ethanol reinforcement and consumption (McBride, 2002; 
Gonzales et al., 2004). A reduction in cellular 3α,5α-THP would presumably reduce the 
amount of GABAA receptor mediated neuronal inhibition, which may increase firing of 
mesolimbic dopamine neurons and CeA circuitry involved in ethanol reinforcement. In 
the NAc, reductions of 3α,5α-THP were isolated to the “shore” (core-shell border), as no 
changes in 3α,5α-THP were detected exclusively in the shell or core. This is an 
interesting finding since ethanol associated cues and operant self-administration of 
ethanol both increase dopamine release in the “shore” following operant training 
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(Howard et al., 2009), but in the core or shell only ethanol associated cues increase 
dopamine release following operant training. It is important to note, however, that acute 
systemic ethanol administration increases dopamine release in the NAc core and shell 
(Imperato and Di Chiara, 1986; Yim et al., 2000) where ethanol did not alter 3α,5α-THP 
levels. Administration of 3α,5α-THP produces biphasic effects on ethanol consumption 
(Janak et al., 1998; Ford et al., 2005; Ford et al., 2007; Finn et al., 2010) and dopamine 
release in the NAc (Motzo et al., 1996; Rouge-Pont et al., 2002). Furthermore, 3α,5α-
THP modulates ethanol’s effects on mPFC dopamine content (Dazzi et al., 2002). 
Therefore, investigating possible interactions of 3α,5α-THP and dopaminergic activity in 
the mesocorticolimbic system may be valuable in the effort to reduce ethanol 
consumption via neuroactive steroid modulation. 
 The current data show that ethanol produces divergent brain region and cell layer 
specific changes in cellular 3α,5α-THP concentrations. These divergent effects suggest 
that ethanol induces local regulation of 3α,5α-THP levels. These changes in 3α,5α-THP 
levels likely contribute to the neurophysiological and behavioral effects of ethanol in rats. 
Examining the mechanisms by which ethanol alters levels of 3α,5α-THP across the brain 
may lead to new therapeutic strategies for treating alcohol use disorders.  
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FIGURES AND TABLES 
 
Figure 2.1: Effect of acute ethanol administration (2g/kg, i.p.) on 3α,5α-THP 
immunoreactivity in the mPFC and pyramidal cell layer of the CA1 hippocampus. (A) 
Ethanol administration increased 3α,5α-THP immunoreactivity in the mPFC compared to 
saline controls. Representative photomicrographs (10x) of 3α,5α-THP immunoreactivity 
in the mPFC (3.20 mm relative to bregma) following saline (n=8) or ethanol (n=7) 
administration. (B) Ethanol administration increased 3α,5α-THP immunoreactivity in the 
pyramidal cell layer of the CA1 hippocampus compared to saline controls. Representative 
photomicrographs (10x) of 3α,5α-THP immunoreactivity in CA1 pyramidal cells 
(highlighted in rectangle, -2.80 mm relative to bregma) following saline (n=8)  or ethanol 
(n=8)  administration. Ethanol (2g/kg, i.p.) or saline were administered 60 min prior to 
tissue fixation and collection. Data are expressed as mean positive pixels/mm
2   SEM. * 
p < 0.05, ** p < 0.01 compared to saline administration. Medial prefrontal cortex 
(mPFC), ethanol (EtOH), Cornu Ammonis area 1 (CA1). 
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Figure 2.2: Effect of acute ethanol administration (2g/kg, i.p.) on 3α,5α-THP 
immunoreactivity in the polymorph and granule cell layers of the DG. (A) Ethanol 
administration increased 3α,5α-THP immunoreactivity in the polymorph cell layer 
compared to saline controls. (B) Ethanol administration did not alter 3α,5α-THP 
immunoreactivity in the granule cell layer compared to saline controls. (C) 
Representative photomicrographs (10x) of 3α,5α-THP immunoreactivity in the 
polymorph cell layer (oval) and granule cell layer (rectangle) of the DG (-3.14 mm 
relative to bregma) following saline (n=8) or ethanol (n=8) administration. Ethanol 
(2g/kg, i.p.) or saline were administered 60 min prior to tissue fixation and collection. 
Data are expressed as mean positive pixels/mm
2   SEM. *** p < 0.001 compared to 
saline administration. Dentate gyrus (DG), ethanol (EtOH). 
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Figure 2.3: Effect of acute ethanol administration (2g/kg, i.p.) on 3α,5α-THP 
immunoreactivity in the PVN of the hypothalamus and BNST. (A) Ethanol 
administration increased 3α,5α-THP immunoreactivity in the PVN compared to saline 
controls. Representative photomicrographs (10x) of 3α,5α-THP immunoreactivity in the 
PVN (-1.88 mm relative to bregma) following saline (n=8) or ethanol (n=8) 
administration. (B) Ethanol administration also increased 3α,5α-THP immunoreactivity 
in the BNST compared to saline controls. Representative photomicrographs (10x) of 
3α,5α-THP immunoreactivity in BNST (-0.26  mm relative to bregma) following saline 
(n=8)  or ethanol (n=7) administration. Ethanol (2g/kg, i.p.) or saline were administered 
60 min prior to tissue fixation and collection. Data are expressed as mean positive 
pixels/mm
2   SEM. * p < 0.05, ** p < 0.01 compared to saline administration. 
Paraventricular nucleus (PVN), bed nucleus of the stria terminalis (BNST), ethanol 
(EtOH). 
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Figure 2.4: Effect of acute ethanol administration (2g/kg, i.p.) on 3α,5α-THP 
immunoreactivity in NAc “shore” (core/shell border), DMS, and VTA. (A) Ethanol 
administration reduced 3α,5α-THP immunoreactivity in the NAc “shore” compared to 
saline controls. Representative photomicrographs (10x) of 3α,5α-THP immunoreactivity 
in NAc “shore” (1.60 mm relative to bregma) following saline (n=7) or ethanol (n=7) 
administration. (B) Ethanol administration did not alter 3α,5α-THP immunoreactivity in 
the DMS compared to saline controls. Representative photomicrographs (10x) of 3α,5α-
THP immunoreactivity in DMS (1.60 mm relative to bregma) following saline (n=8) or 
ethanol (n=7) administration. (C) Ethanol administration did not alter 3α,5α-THP 
immunoreactivity in the VTA compared to saline controls. Representative 
photomicrographs (10x) of 3α,5α-THP immunoreactivity in the VTA  (-5.30 mm relative 
to bregma) following saline (n=7) or ethanol (n=7) administration. Ethanol (2g/kg, i.p.) 
or saline were administered 60 min prior to tissue fixation and collection. Data are 
expressed as mean positive pixels/mm
2   SEM. ** p < 0.01 compared to saline 
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administration. Nucleus accumbens (NAc), dorsomedial striatum (DMS), ventral 
tegmental area (VTA), ethanol (EtOH). 
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Figure 2.5: Effect of acute ethanol administration (2g/kg, i.p.) on 3α,5α-THP 
immunoreactivity in CeA,  lateral amygdala, and basolateral amygdala. (A) Ethanol 
administration reduced 3α,5α-THP immunoreactivity in the CeA compared to saline 
controls. Representative photomicrographs (10x) of 3α,5α-THP immunoreactivity in CeA 
(-2.56 mm relative to bregma) following saline (n=8) or ethanol (n=8) administration. (B) 
Ethanol administration did not alter 3α,5α-THP immunoreactivity in the lateral amygdala 
compared to saline controls. Representative photomicrographs (10x) of 3α,5α-THP 
immunoreactivity in the lateral amygdala (-2.56 mm relative to bregma) following saline 
(n=8) or ethanol (n=7) administration. (C) Ethanol administration did not alter 3α,5α-
THP immunoreactivity in the basolateral amygdala compared to saline controls. 
Representative photomicrographs (10x) of 3α,5α-THP immunoreactivity in the 
basolateral amygdala (-2.56 mm relative to bregma) following saline (n=7) or ethanol 
(n=7) administration. Ethanol (2g/kg, i.p.) or saline were administered 60 min prior to 
tissue fixation and collection. Data are expressed as mean positive pixels/mm
2   SEM.    
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* p < 0.05 compared to saline administration. Central nucleus of the amygdala (CeA), 
ethanol (EtOH). 
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 EFFECTS OF ADRENALECTOMY ON ETHANOL-CHAPTER 3.
INDUCED CHANGES IN 3,5-THP IMMUNOHISTOCHEMISTRY  
 
INTRODUCTION 
Neuroactive steroids are endogenous neuromodulators capable of altering 
neuronal activity. Synthesis of neuroactive steroids occurs centrally in the brain and 
peripherally in the adrenal glands and gonads. The 5α-reduced pregnane steroids, 
(3,5)-3-hydroxypregnan-20-one (3α,5α-THP or allopregnanolone) and (3,5)-3,21-
dihydroxypregnan-20-one (3α,5α-THDOC), are positive allosteric modulators of γ-
aminobutyric acid type A (GABAA) receptors. GABAA receptors are the primary 
inhibitory receptor family in the brain, which mediate many of the behavioral effects of 
ethanol. Both 3α,5α-THP and 3α,5α-THDOC enhance neuronal inhibition at known 
binding sites on GABAA receptor α-subunits (Hosie et al., 2006), and produce behavioral 
effects similar to those produced by ethanol. These GABAergic neuroactive steroids are 
very potent positive modulators of GABAA receptors, producing pharmacological effects 
in nanomolar concentrations (Morrow et al., 1987), and modulating GABAergic steroid 
levels may have therapeutic value for treating multiple psychiatric disorders (Uzunova et 
al., 1998; Strohle et al., 2002; Marx et al., 2006; Rasmusson et al., 2006; Morrow, 2007). 
Evidence suggests ethanol increases levels of 3α,5α-THP and 3α,5α-THDOC, 
which contribute to ethanol’s behavioral and electrophysiological effects in rodents. 
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Ethanol activates the hypothalamic-pituitary-adrenal (HPA) axis (Boyd et al., 2010) 
leading to physiologically significant increases of 3α,5α-THP and 3α,5α-THDOC in the 
blood plasma, cerebral cortex, and hippocampus (Barbaccia et al., 1999; VanDoren et al., 
2000; Porcu et al., 2009). Adrenalectomy or inhibition of 5α-reduced steroid synthesis 
with the 5α-reductase (5α-R) inhibitor finasteride reduces some of the behavioral effects 
of ethanol, including the anticonvulsant (VanDoren et al., 2000), anti-depressant-like 
(Hirani et al., 2002), hypnotic (Khisti et al., 2003), and anxiolytic-like (Hirani et al., 
2005) effects in rats. Finasteride also blocks ethanol inhibition of neuron firing in the 
medial septum (VanDoren et al., 2000), the hippocampus both in vivo (Tokunaga et al., 
2003b) and in vitro (Sanna et al., 2004), and long-term potentiation (LTP) in 
hippocampal slice preparations (Tokuda et al., 2011). Importantly, finasteride also 
reduces some of the subjective effects of alcohol in healthy men (Pierucci-Lagha et al., 
2005). Taken together, these findings suggest ethanol-induced elevations of 3α,5α-THP 
and 3α,5α-THDOC contribute to many of the physiological and behavioral effects of 
ethanol. 
In vivo studies suggest ethanol-induced elevations of 3α,5α-THP in the cerebral 
cortex are dependent on the adrenal glands (Khisti et al., 2003; O'Dell et al., 2004; Porcu 
et al., 2004). In vitro studies, however, suggest ethanol produces local brain synthesis of 
3α,5α-THP in hippocampal tissue from intact (Sanna et al., 2004; Tokuda et al., 2011) 
and adrenalectomized/gonadectomized (Follesa et al., 2006) rats. Therefore, an important 
question is whether ethanol can alter brain synthesis of 3α,5α-THP in vivo, independent 
of adrenal influence. The answer to this question has remained elusive due to limitations 
in 3α,5α-THP measurements. Most experiments measuring ethanol-induced changes in 
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3α,5α-THP have used radioimmunoassay (RIA) or gas chromatography—mass 
spectroscopy (GC-MS), which lack the sensitivity to measure 3α,5α-THP in many brain 
regions. 
We have recently demonstrated ethanol-induced changes in immunohistochemical 
labeling of 3α,5α-THP in several rat brain regions that are implicated in alcohol use 
disorders. This technique displays the sensitivity to detect changes in 3α,5α-THP 
immunoreactivity associated with corresponding changes in electrophysiological 
measurements (Saalmann et al., 2006; Tokuda et al., 2011). Ethanol produces divergent 
changes in cellular 3α,5α-THP levels that are brain region and cellular population 
specific (Cook et al., 2013). For example, ethanol increased cellular 3α,5α-THP levels in 
the medial prefrontal cortex (mPFC), hippocampal CA1 pyramidal cell layer, 
polymorphic cell layer of the dentate gyrus (DG), bed nucleus of the stria terminalis 
(BNST), and the paraventricular nucleus (PVN) of the hypothalamus. In contrast, ethanol 
reduced cellular 3α,5α-THP levels in the nucleus accumbens (NAc) shore (core-shell 
border) and the central nucleus of the amygdala (CeA). Interestingly, no changes were 
observed in the granule cell layer of the DG, dorsomedial striatum, lateral or basolateral 
amygdala, or the ventral tegmental area. Taken together, these region specific effects of 
ethanol on cellular 3α,5α-THP suggest there may be local brain synthesis of 3α,5α-THP 
independent of the adrenal glands and novel mechanisms that reduce cellular 3α,5α-THP.  
In the present study, we tested whether ethanol-induced changes in immunohistochemical 
labeling of 3α,5α-THP are dependent upon the adrenal glands. We used male Wistar rats 
that had undergone ADX or sham surgery and measured the ability of ethanol (2g/kg, 
i.p.) to alter cellular 3α,5α-THP levels in brain regions/cellular populations where we had 
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previously observed ethanol-induced changes in 3α,5α-THP. We also investigated the 
effects of ethanol on 3,5-THP levels in perfused and non-perfused rat brain in order to 
determine the contribution of circulating steroids in brain measurements of 3α,5α-THP 
using RIA. Finally, we evaluated the effect of the pentobarbital anesthetic on 3α,5α-THP 
levels in the cerebral cortex and hippocampus.  
MATERIALS AND METHODS 
Subjects 
For the ADX experiments adult male Wistar rats (~275 g/8-11 per group) that had 
undergone ADX or sham surgery were purchased from Harlan Laboratories 
(Indianapolis, IN, USA). The animals were single housed in Plexiglass cages with food 
and water (animals that underwent ADX received 0.9% saline instead of water) available 
ad libitum. Animals were sacrificed 7 days following surgery and approximately 24hr 
after arriving in the colony room. For the RIA studies male Wistar rats (5-14 per group) 
were purchased from Harlan Laboratories (Indianapolis, IN, USA) and stayed in the 
colony room for 6 weeks to reach adulthood. The animals habituated to handling and 
saline i.p. saline injections for 1 week prior to the experiment. The colony room was 
maintained on a normal 12 hr light-dark cycle (light onset at 0700 hr) and at a constant 
temperature of 22 ± 2 C and relative humitity of 65%. Experiments were conducted 
between 0800 and 1300 hr to minimize potential circadian fluctuation in neuroactive 
steroid levels.  
Ethanol (2g/kg, 20% v/v in saline) or saline were administered by i.p. injection 60 
minutes before transcardial perfusion. Animal care and handling procedures followed 
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National Institutes of Health Guidelines under University of North Carolina at Chapel 
Hill Institutional Animal Care and Use Committee approved protocols.    
Radioimmunoassay (RIA) 
Prior to RIA, 3α,5α-THP was extracted from freshly frozen cerebral cortex or 
hippocampus. Recovery was monitored by incorporation of 4000 dpm of [
3
H]-3α,5α-
THP. Brain samples were homogenized in 2.5ml 0.3 N NaOH with a sonic dismembrator 
and extracted three times in 3ml aliquots of 10% (v/v) ethyl acetate in heptane. Aliquots 
were combined and 5ml of heptane was added to each sample. The extracts were run 
through solid phase silica columns, washed in pentane, and steroids of similar polarity to 
3α,5α-THP were eluted off the column by 25% acetone in pentane. Eluant was dried, and 
steroids reconstituted in 50µl isopropanol and 150µl 50% sodium phosphate/bovine 
serum albumin assay buffer. Extraction efficiency was determined in 50µl the 
reconstituted extract by liquid scintillation spectroscopy. The remaining 150µl was used 
in RIA determination of 3α,5α-THP. 
Sample extracts in sodium phosphate/bovine serum albumin assay buffer with 
incubated with sheep polyclonal 3α,5α-THP antiserum (obtained from Dr. Robert Purdy, 
Scripps Research Institute) and [
3
H]-3α,5α-THP for 1.5-2hr. Unbound [3H]-3α,5α-THP 
was removed by centrifugation after adding dextran-coated charcoal. The supernatant 
was mixed with Ecoscint H (National Diagnostics) and [
3
H]-3α,5α-THP was measured in 
a scintillation counter. Samples were compared with a concurrently run 3α,5α-THP 
standard curve. The resulting curves were analyzed using a one-site competition model 
(Prism, GraphPad Software, La Jolla, CA, USA) for EC50 values. 
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Immunohistochemistry 
 Fifty-three minutes after ethanol (2g/kg) or saline injection the animals were 
anesthetized with pentobarbital (100mg/kg, i.p.; Professional Compounding Centers of 
America, Houston, TX, USA) and transcardially perfused approximately 1hr following 
ethanol or saline injection with phosphate buffered saline (PBS) followed by 4% 
paraformaldehyde. Tissue was post-fixed in 4% paraformaldehyde for 24hr at 4°C, 
sectioned coronally at 40μm on a vibrating microtome, and stored at -30°C. Pentobarbital 
does not alter 3α,5α-THP levels using this procedure, and blood perfusion does not alter 
brain levels of 3α,5α-THP in intact animals using RIA (unpublished data). 
 Immunohistochemical assays were performed using a procedure modified from 
(Saalmann et al., 2007) and previously described in detail (Cook et al., 2013). Briefly, no 
detergents or organic solvents were used to prevent the possibility of neuroactive steroid 
leaching. Free floating brain sections (3-4 sections/animal/brain region) were rinsed, 
blocked in 10% rabbit serum, and incubated in sheep affinity purified anti-3α,5α-THP 
antiserum (purchased from Dr. R.H. Purdy) at a 1:2500 dilution for 48 hr at 4°C. A rabbit 
anti-sheep biotinylated secondary antibody (1:200; Vector laboratories, Burlingame, CA, 
USA) was used in collaboration with the Vectastain Elite ABC kit (Vector Laboratories, 
Burlingame, CA, USA) and immunoreactivity was visualized with 3,3’-diaminobenzidine 
(Sigma-Aldrich, St. Louis, MO, USA) using the manufacturers’ recommended 
procedures. 
Immunohistochemical analysis 
Immunoreactivity was visualized using an Olympus CX41 light microscope 
(Olympus America, Center Valley, PA, USA) and images were captured with a digital 
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camera (Regita model, QImaging, Burnaby, BC). Image analysis software (Bioquant Life 
Sciences version 8.00.20; Bioquant Life Sciences, Nashville, TN, USA) that utilizes 
linear integrated optical density was used for comparing relative changes in 
immunoreactivity between groups. The microscope, camera, and software were 
background corrected and normalized to preset light levels to ensure fidelity of data 
acquisition. Immunoreactive positive pixel count measurements were calculated from a 
defined region (e.g., brain region), divided by the area of the region in square millimeters, 
and expressed as positive pixels/mm
2
. Data were acquired from 3-4 sections/animal/brain 
region, and averaged within a brain region for an individual animal to obtain one value 
per subject. Inter-rater reliability was determined by calculating the intraclass-correlation 
coefficient for two raters blind to the experimental conditions. Data from the NAc and 
mPFC were chosen for intraclass-correlation analysis and values of r = 0.93 (p < 0.001) 
and r = 0.88 (p < 0.05) were obtained, respectively. Intraclass-correlation coefficient was 
calculated using MATLAB (MathWorks, Natick, MA, USA). Immunoreactivity was 
measured separately for each brain region and statistically analyzed using two-way 
between subjects design ANOVA (Prism, GraphPad Software, La Jolla, CA, USA). A 
priori planned comparisons were performed to compare ethanol to saline administration 
in the mPFC using Student’s t-test (Prism, GraphPad Software, La Jolla, CA, USA).  
Brain region analyses were performed using histological coordinates as follows: mPFC 
(+3.00 to +2.20 AP), hippocampal CA1 pyramidal cell layer (-2.56 to -3.30 AP), DG 
polymorphic cell layer (-2.56 to -3.30 AP), BNST (-0.26 to -0.40 AP), PVN of the 
hypothalamus (-1.30 to -2.12 AP), NAc (+1.70 to +1.00 AP), and CeA (-2.12 to -2.80 
 54 
AP). All analyses were based on coordinates relative to bregma in the Rat Brain Atlas 
(Paxinos and Watson, 1998). 
RESULTS 
Effects of transcardial perfusion or pentobarbital administration on 3α,5α-THP 
measurements in the whole cerebral cortex or hippocampus using RIA 
 Previous IHC results had found a discrepancy in the magnitude of ethanol-
induced increases of 3α,5α-THP between IHC and RIA measurement. Using IHC we 
observed a 24% and 32% increase of 3α,5α-THP in the mPFC and CA1 pyramidal cells, 
respectively. RIA studies have shown 2-17 fold increases in the whole cortex (Barbaccia 
et al., 1999; VanDoren et al., 2000; Khisti et al., 2004; Boyd et al., 2010) and 4-11 fold 
increase in whole hippocampus (Barbaccia et al., 1999; Khisti et al., 2004). Therefore, 
since IHC brains are perfused, we tested whether the blood present in RIA tissue samples 
contribute to the discrepancy in 3α,5α-THP magnitude. As expected, there was a main 
effect of ethanol in the cerebral cortex [F (1,38) = 76.78, p < 0.0001] (Fig. 3.1A) and 
hippocampus [F (1,33) = 107.5, p < 0.0001] (Fig. 3.1B), but there was no effect of 
perfusion on 3α,5α-THP levels in the cortex [F (1,38) = 0.19, p = 0.6644] (Fig. 3.1A) or 
hippocampus [F (1,33) = 0.92, p = 0.3433] (Fig. 3.1B).  
To further validate our IHC assay we tested whether the pentobarbital anesthetic 
alters 3α,5α-THP in whole cerebral cortex or hippocampus. There was a main effect of 
ethanol in the cerebral cortex [F (1,33) = 109.5, p < 0.0001] (Fig. 3.1C) and hippocampus 
[F (1,27) = 151.7, p < 0.0001] (Fig. 3.1D), but there was no effect of pentobarbital on 
3α,5α-THP levels in the cortex [F (1,33) = 0.73, p = 0.3987] (Fig. 3.1C) or hippocampus 
[F (1,27) = 0.07, p = 0.7886] (Fig. 3.1D). 
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Ethanol-induced increases of cellular 3α,5α-THP 
Recent work in our lab has shown that ethanol increases 3α,5α-THP 
immunoreactivity in the mPFC, CA1 pyramidal cell layer of the hippocampus, 
polymorphic cell layer of the DG, BNST, and PVN of the hypothalamus (Cook et al., 
2013). Therefore, we tested whether ethanol-induced elevations of 3α,5α-THP in these 
regions are dependent upon adrenal gland activation. Ethanol administration increased 
3α,5α-THP immunoreactivity in the mPFC, but this effect was moderated by 
adrenalectomy (Fig. 3.2A). The two-way ANOVA indicated a main effect of ethanol 
treatment [F (1,34) = 8.18, p < 0.01] and surgery condition [F (1,34) = 9.41, p < 0.005], 
but no significant interaction. Therefore, we performed an a priori planned comparison 
between the sham saline versus sham ethanol and ADX saline versus ADX ethanol 
groups. mPFC 3α,5α-THP immunoreactivity was significantly increased in the sham 
ethanol group compared to the sham saline group [25±11%; t(15)=3.583, p < 0.01], 
similar to previous immunohistochemical results (Cook et al., 2013). However, ethanol 
did not increase 3α,5α-THP in animals that received ADX [2±7%; t(19)=0.937, p > 0.05], 
suggesting that the adrenals contribute to the effects of ethanol in mPFC. The effects of 
ethanol appear uniform across the cortical cell layers (Fig. 3.2C).  
In the hippocampus, ethanol increased 3α,5α-THP immunoreactivity in the CA1 
pyramidal cell layer and the polymorphic cell layer of the DG independent of the adrenal 
glands. In the CA1 pyramidal cell layer, 3α,5α-THP immunoreactivity was increased by 
49±7% in the sham ethanol versus sham saline group and by 48±11% in the ADX ethanol 
versus ADX saline group (main effect of ethanol treatment [F (1,34) = 23.15, p < 
0.0001]) (Fig. 3.3A). In the polymorphic cell layer of the DG, 3α,5α-THP 
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immunoreactivity was increased by 63±10% in the sham ethanol versus sham saline 
group and by 74±11% in the ADX ethanol versus ADX saline group (main effect of 
ethanol treatment [F (1,34) = 61.16, p < 0.0001]) (Fig. 3.3D). 
In the BNST and PVN of the hypothalamus, ethanol increased 3α,5α-THP 
immunoreactivity independent of the adrenal glands. In the BNST, 3α,5α-THP 
immunoreactivity was increased by 43±5% in the sham ethanol versus sham saline group 
and by 40±8% in the ADX ethanol versus ADX saline group (main effect of ethanol 
treatment [F (1,34) = 35.68, p < 0.0001]) (Fig. 3.4A). In the PVN, 3α,5α-THP 
immunoreactivity was increased by 38±10% in the sham ethanol versus sham saline 
group and by 39±7% in the ADX ethanol versus ADX saline group (main effect of 
ethanol treatment [F (1,34) = 27.70, p < 0.0001]) (Fig. 3.4D). 
Ethanol-induced decreases of cellular 3α,5α-THP   
 Recently, we have shown that ethanol administration decreases 3α,5α-THP 
immunoreactivity in the NAc shore and the CeA. Therefore, we tested whether ethanol-
induced reductions of 3α,5α-THP in these regions are dependent on adrenal gland 
activation. In both the NAc shore and the CeA, ethanol reduced cellular 3α,5α-THP 
independent of the adrenals. In the NAc shore, 3α,5α-THP immunoreactivity was 
decreased by 27±5% in the sham ethanol versus sham saline group and by 26±5% in the 
ADX ethanol versus ADX saline group (main effect of ethanol treatment [F (1,34) = 
17.58, p < 0.001]) (Fig. 3.5A). In the CeA, 3α,5α-THP immunoreactivity was decreased 
by 39±2% in the sham ethanol versus sham saline group and by 29±7% in the ADX 
ethanol versus ADX saline group (main effect of ethanol treatment [F (1,34) = 28.74, p < 
0.0001]) (Fig. 3.6A).  
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DISCUSSION 
The goal of the present study was to determine the source of ethanol-induced 
changes in cellular 3α,5α-THP levels in the rat brain. Ethanol-induced elevations of 
3α,5α-THP in the mPFC appear to be dependent on adrenal gland activation. This finding 
is in agreement with studies using RIA to measure 3α,5α-THP in whole cerebral cortex 
(Khisti et al., 2003; Porcu et al., 2004) and GC-MS data measuring 3α,5α-THP in the 
frontal cortex (O'Dell et al., 2004). Interestingly, ethanol-induced elevations of 3α,5α-
THP in the pyramidal cell layer of the hippocampus, polymorphic cell layer of the DG, 
BNST, and PVN were observed following ADX. Therefore, ethanol produces local brain 
synthesis of 3α,5α-THP in these brain regions and cellular populations. Furthermore, the 
ethanol-induced reductions of cellular 3α,5α-THP in the NAc shore and CeA were also 
observed following ADX. Thus, ethanol reduces local cellular levels of 3α,5α-THP in 
these regions independent of adrenal gland activation. The results from the sham saline 
and sham ethanol groups in the current study replicate previous immunohistochemical 
findings (Cook et al., 2013). It is important to note that this previous 
immunohistochemical study found no change in cellular levels of 3α,5α-THP in the 
dorsomedial striatum, granule cell layer of the DG, ventral tegmental area, or the lateral 
or basolateral amygdala. Therefore, ethanol-induced changes in cellular 3α,5α-THP are 
bidirectional, brain region/cell population specific, and occur locally in the rat brain. Our 
previous IHC study had shown that the magnitude of the effect of ethanol on 3α,5α-THP 
levels using IHC is much smaller than what has been observed using RIA. Here, we show 
that circulating blood does not contribute to RIA measurements of 3α,5α-THP in the 
whole cerebral cortex or hippocampus. Finally, to further validate the 3α,5α-THP IHC 
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assay showed that the pentobarbital anesthetic does not alter 3α,5α-THP levels in whole 
cerebral cortex or hippocampus.  
The current IHC results and previous reports using RIA or GC-MS all suggest 
that ethanol-induced elevations of 3α,5α-THP in the cerebral cortex are dependent on the 
adrenal glands or the pituitary (Boyd et al., 2010). It is not clear why there is a 
dependence on HPA activation to observe cerebral cortical elevations of 3α,5α-THP, but 
one possibility is that there is a lack of precursor in the cortex. Indeed, it has previously 
been shown that administration of 5α-dihydroprogesterone (5α-DHP), the immediate 
precursor of 3α,5α-THP, restores ethanol-induced increases of 3α,5α-THP in the cerebral 
cortex and corresponding effects of ethanol on loss of righting reflex following ADX 
(Khisti et al., 2003). It has also been shown that de novo adrenal synthesis of the 
cholesterol transporter, steroidogenic acute regulatory protein (StAR), is necessary for 
ethanol-induced increases of 3α,5α-THP in the cerebral cortex (Boyd et al., 2010). StAR 
transports cholesterol to the inner mitochondrial membrane where it is converted to 
pregnenolone by cytochrome P450 side chain cleavage (P450scc). Therefore, de novo 
StAR synthesis in the adrenals may be necessary to provide precursor and/or 3α,5α-THP 
to the cerebral cortex following ethanol administration. Previous work has shown that 
acute ethanol increases StAR and P450scc mRNA expression in the rat frontal cortex 
(Kim et al., 2003), however, no increase in StAR protein was found in whole cortex 
(Boyd et al., 2010). The synthesis of 3α,5α-THP is accomplished by 5α-R converting 
progesterone to 5α-DHP, which 3α-HSD then converts to 3α,5α-THP. Acute ethanol 
administration increases 5α-R type 1 (5α-RI) and 3α-HSD mRNA expression in the 
frontal cortex of rats (Kim et al., 2003). Taken together, it appears that ethanol-induced 
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increases of 3α,5α-THP in the cerebral cortex are dependent on adrenal derived 
precursor, which is converted to 3α,5α-THP by locally synthesized steroidogenic 
enzymes. 
The current results in the hippocampal formation agree with the previous in vitro 
studies that have shown ethanol-induced local brain synthesis of 3α,5α-THP. For 
example, it was first shown using RIA that incubation with ethanol (50 or 100 mM) can 
increase 3α,5α-THP in hippocampal minces from intact rats (Sanna et al., 2004) and rats 
that had undergone ADX/gonadectomy (Follesa et al., 2006). More recently, it was 
shown that ethanol increases cellular 3α,5α-THP in CA1 pyramidal cells using IHC with 
fluorescent detection of 3α,5α-THP (Tokuda et al., 2011). In each of these in vitro 
studies, ethanol induction of 3α,5α-THP was shown to alter neuronal function using 
electrophysiological measures. In the current study, we show that ethanol increases 
3α,5α-THP immunoreactivity in the CA1 pyramidal cell layer as well as the polymorphic 
cell layer of the DG, independent of adrenal gland activation. Furthermore, ethanol’s 
ability to stimulate brain synthesis of 3α,5α-THP in the hippocampal formation is isolated 
to specific cellular populations, since we did not previously observe ethanol-induced 
changes of 3α,5α-THP in the granule cell layer of the DG (Cook et al., 2013). The CA1 
pyramidal cells, polymorphic DG, and granule cell layer of the DG all exhibit dense 
3α,5α-THP staining. Therefore, the presence of this very specific effect of ethanol on 
cellular 3α,5α-THP in the hippocampus is intriguing and may underlie neuron specific 
responses to ethanol in the hippocampal formation. 
Ethanol also increased 3α,5α-THP immunoreactivity in the PVN of the 
hypothalamus and the BNST, independent of the adrenal glands. The PVN and the BNST 
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are involved in stress, emotion, and ethanol responses (Armario, 2010; Cui et al., 2012; 
Koob, 2013), and we have previously shown that ethanol increases cellular 3α,5α-THP in 
these regions (Cook et al., 2013). It has also been shown that GABAergic neuroactive 
steroids contribute to negative feedback on the HPA axis at the level of the hypothalamus 
in rats (Owens et al., 1992; Patchev et al., 1994; Patchev et al., 1996), and activate the 
stress response in the hypothalamus of C57BL/6J mice (Sarkar et al., 2011). The present 
data suggest that ethanol-induced changes of cellular 3α,5α-THP in the PVN and BNST 
are independent of adrenal activation. Other studies are clearly needed to understand the 
physiological and behavioral impact these local elevations of 3α,5α-THP produce in the 
PVN and BNST. 
Ethanol-induced reductions of cellular 3α,5α-THP in the NAc and CeA were also 
shown to occur independent of adrenal activation. Ethanol’s ability to change local 
cellular levels of 3α,5α-THP within the NAc and CeA is particularly interesting since 
these brain regions are strongly associated with alcohol reinforcement and consumption 
(McBride, 2002; Gonzales et al., 2004), and exogenous 3α,5α-THP has been shown to 
modulate ethanol self-administration. For example, several studies have shown that 
3α,5α-THP alters ethanol consumption (Morrow et al., 2001; Ford et al., 2005; Ford et 
al., 2007) and reinforcement (Janak et al., 1998; Janak and Michael Gill, 2003). Ethanol-
induced reductions of cellular 3α,5α-THP would most likely decrease GABAA receptor 
mediated inhibition, which may increase firing of mesolimbic dopamine neurons and 
CeA circuitry involved in ethanol reinforcement. We have previously shown that the 
reduction of 3α,5α-THP in the NAc is isolated to the NAc shore (core-shell border), as no 
change in cellular 3α,5α-THP is observed in the core or shell alone (Cook et al., 2013). 
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Previous studies have shown that 3α,5α-THP administration produces biphasic effects on 
dopamine release in the NAc (Motzo et al., 1996; Rouge-Pont et al., 2002), and 
modulates ethanol’s effects on dopamine content in the mPFC (Dazzi et al., 2002). 
Therefore, investigating interactions between 3α,5α-THP levels and dopaminergic 
activity in the mesocorticolimbic system may aid in the effort to reduce ethanol 
consumption via neuroactive steroid modulation. 
Significance on Neuronal Activity and Potential Mechanisms of Ethanol-Induced 
Changes in Local 3α,5α-THP Levels 
 A previous study using IHC determined that 3α,5α-THP is located in principle 
projecting GABAergic and glutamatergic neurons, but not in interneurons or glial cells 
(Saalmann et al., 2007). This pattern of 3α,5α-THP expression corresponds with the 
expression of the biosynthetic enzymes 5α-R and 3α-HSD needed for 3α,5α-THP 
synthesis and metabolism (Agis-Balboa et al., 2006). Therefore, it has been suggested 
that a major role of 3α,5α-THP may be to modulate neurocircuitry. As previously 
mentioned, evidence suggests that ethanol-induced increases in 3α,5α-THP contribute to 
the behavioral effects of ethanol in rats and the subjective effects of alcohol in humans. 
The contribution of 3α,5α-THP to the pharmacological effects of ethanol is likely due to 
potentiation of GABAA receptors, or reduced GABAA potentiation where 3α,5α-THP is 
reduced, across many brain regions and cellular populations. Ethanol-induced changes in 
3α,5α-THP have been shown to alter neurophysiology in the hippocampus. For example, 
ethanol (1.5g/kg) reduces spontaneous firing of pyramidal cells in the hippocampus of 
anesthetized rats, which is prevented by finasteride (Tokunaga et al., 2003b). In isolated 
hippocampal tissue, ethanol (50, 100mM) increases 3α,5α-THP, with concurrent 
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increases in amplitude of spontaneous and evoked IPSCs in CA1 pyramidal cells (Sanna 
et al., 2004), the latter of which is prevented by finasteride. Furthermore, in hippocampal 
slices, ethanol (60mM) increases 3α,5α-THP immunofluorescence and inhibits LTP in 
CA1 pyramidal cells (Tokuda et al., 2011). Importantly, pretreatment with finasteride 
prevents the increase in 3α,5α-THP immunofluorescence and ethanol’s ability to inhibit 
LTP. Thus, 3α,5α-THP appears to mediate ethanol’s effects on synaptic plasticity in CA1 
pyramidal cells. In the present study, ethanol increased 3α,5α-THP in the CA1 pyramidal 
cell layer and the polymorphic cell layer of the DG. The most abundant cells in the 
polymorphic DG are mossy cells, which project to the molecular and granule cell layers 
of the DG (Amaral et al., 2007), with the granule cells being the only projection from the 
DG to the hippocampus. Ethanol-induced increases in cellular 3α,5α-THP within 
hippocampal pyramidal cells and the polymorphic DG may contribute to ethanol’s effects 
on memory and cognition by altering neuronal activity and synaptic plasticity. 
 The ethanol-induced changes in 3α,5α-THP levels in other brain regions 
examined in the present study likely modulate neuronal activity as well. The ability of 
ethanol-induced elevations of 3α,5α-THP to modulate neuronal activity is not isolated to 
the hippocampus. Outside the hippocampus, ethanol-induced elevations of GABAergic 
neuroactive steroids inhibit spontaneous firing of medial septum/diagonal band of Broca 
neurons (VanDoren et al., 2000). In the present study we observed increases of 3α,5α-
THP in the mPFC, BNST and PVN. It is not clear how elevations of 3α,5α-THP may 
alter neuronal activity in these regions, but we would expect an increase of inhibitory 
tone. We also observed ethanol-induced reductions in local cellular levels of 3α,5α-THP 
in the NAc shore and the CeA. Ethanol-induced reductions of cellular 3α,5α-THP would 
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most likely decrease GABAA receptor mediated inhibition. More studies are clearly 
needed to determine the extent to which these ethanol-induced changes of 3α,5α-THP 
contribute to the neurophysiological and behavioral effects of ethanol.  
 The presence of divergent local changes in cellular 3α,5α-THP suggest that 
ethanol may alter local synthesis and/or metabolism of 3α,5α-THP. One possibility is that 
ethanol alters the expression and/or activity of the cholesterol transporters and/or 
steroidogenic enzymes. Acute ethanol administration increases StAR mRNA in the 
hippocampus (Kim et al., 2003). In the hypothalamus, acute ethanol increases mRNA 
levels of StAR, P450scc, and 3α-HSD (Kim et al., 2003). Currently, there are no data 
examining ethanol’s effects on steroidogenic enzymes in the BNST. Similarly, there are 
no data examining ethanol’s effects on steroidogenic enzymes in the NAc or CeA where 
we observed ethanol-induced reductions in 3α,5α-THP. Chronic intermittent ethanol, 
however, has been shown to reduce 3α,5α-THP in the hippocampus along with 
concomitant decreases in 5α-R type I and 3α-HSD mRNA (Cagetti et al., 2004). 
Therefore, ethanol may alter levels and/or activity of steroid biosynthetic enzymes to 
produce divergent brain region specific changes in 3α,5α-THP. Ultimately, the changes in 
neuroactive steroid levels may depend on the combination of cholesterol transporter 
and/or synthetic enzymes expressed in a particular cell type. 
 An alternative possibility to explain ethanol-induced reductions of cellular 3α,5α-
THP in the NAc shore and the CeA is extra-neuronal redistribution of 3α,5α-THP. 
GABAergic neuroactive steroids have been proposed to act on GABAA receptors via 
lateral diffusion through the cell membrane to access transmembrane binding sites (Akk 
et al., 2007), or by a paracrine or autocrine mechanism (Herd et al., 2007). Although 
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there is no direct evidence for active release of 3α,5α-THP, we cannot rule out the 
possibility that ethanol causes a release or redistribution of 3α,5α-THP into the 
extracellular space. 
 In the present study, we show for the first time in vivo that ethanol can change 
local brain levels of 3α,5α-THP independent of circulating steroids. Local changes in 
cellular 3α,5α-THP levels are divergent, brain region and cellular population specific, and 
were only observed in subcortical regions. In the mPFC, ethanol’s ability to increase 
3α,5α-THP is dependent on adrenal activation, perhaps due to a lack of local cholesterol 
transporter activity and/or precursor availability. These findings illustrate the fact that 
ethanol dynamically regulates 3α,5α-THP concentrations with a high degree of 
anatomical specificity. Furthermore, the changes observed in 3α,5α-THP levels likely 
contribute to the neurophysiological and behavioral effects of ethanol in rats. 
Understanding the mechanisms by which ethanol alters local brain levels of 3α,5α-THP 
may lead to new therapeutic strategies for treating alcohol use disorders. 
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FIGURES AND TABLES 
 
Figure 3.1: Effect of ethanol (2g/kg, i.p.) on 3α,5α-THP levels in the whole cerebral 
cortex or hippocampus following perfusion or pentobarbital (PB) administration. Ethanol 
increases 3α,5α-THP in both the (A) cerebral cortex and (B) hippocampus, which was not 
altered by perfusion. Ethanol increased 3α,5α-THP in both the (C) cerebral cortex and 
(D) hippocampus, which was not altered by PB administration. Ethanol or saline were 
administered 60 minutes prior to tissue collection. PB was administered 7 minutes prior 
to tissue collection. Data are expressed as mean nanogram 3α,5α-THP per gram of tissue 
± SEM. Pentobarbital, PB. 
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Figure 3.2: Effect of ethanol (2g/kg, i.p.) on 3α,5α-THP immunoreactivity in the mPFC 
of rats subjected to sham surgery or ADX. (A) Ethanol increases 3α,5α-THP 
immunoreactivity in the mPFC following sham surgery, but not ADX, compared to saline 
controls. (B) The red box indicates the location (3.20 mm relative to bregma) of 
representative photomicrographs. (C) Representative photomicrographs (10x) of 3α,5α-
THP immunoreactivity in the mPFC of sham saline (n=8), sham ethanol (n=9), ADX 
saline (n=10), and ADX ethanol (n=11) animals. Ethanol or saline were administered 60 
minutes prior to tissue fixation and collection. Data are expressed as mean positive 
pixels/mm
2 
± SEM. * p < 0.01 compared to saline administration. mPFC, medial 
prefrontal cortex; Sham, sham adrenalectomy surgery; ADX, adrenalectomy. 
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Figure 3.3: Effect of ethanol (2g/kg, i.p.) on 3α,5α-THP immunoreactivity in the CA1 
hippocampus and polymorphic cell layer of the DG following sham surgery or ADX.               
(A) Ethanol increases 3α,5α-THP immunoreactivity in the CA1 pyramidal cell layer after 
sham surgery and ADX, compared to saline controls. (B) The red box indicates the 
location (-3.14 mm relative to bregma) of representative photomicrographs within the 
hippocampus. (C) Representative photomicrographs (10x) of 3α,5α-THP 
immunoreactivity in the CA1 pyramidal cell layer of sham saline (n=8), sham ethanol 
(n=9), ADX saline (n=10), and ADX ethanol (n=11) animals. (D) Ethanol increases 
3α,5α-THP immunoreactivity in the polymorphic cell layer of the DG following sham 
surgery or ADX, when compared to saline controls. (E) The red box indicates the 
location (-3.60 mm relative to bregma) of representative photomicrographs within the 
DG. (F) Representative photomicrographs (10x) of 3α,5α-THP immunoreactivity in the 
polymorphic cell layer of the DG (oval). Ethanol or saline were administered 60 minutes 
prior to tissue fixation and collection. Data are expressed as mean positive pixels/mm
2 
± 
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SEM. * indicates main effect of ethanol treatment, p < 0.0001. CA1, Cornu Ammonis 
area 1; DG, dentate gyrus; Sham, sham adrenalectomy surgery; ADX, adrenalectomy. 
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Figure 3.4: Effect of ethanol (2g/kg, i.p.) on 3α,5α-THP immunoreactivity in the BNST 
and PVN of the hypothalamus following sham surgery or ADX. (A) Ethanol increases 
3α,5α-THP immunoreactivity in the BNST after sham surgery and ADX, when compared 
to saline controls. (B) The red box indicates the location (-0.26 mm relative to bregma) of 
representative photomicrographs within the BNST. (C) Representative photomicrographs 
(10x) of 3α,5α-THP immunoreactivity in the BNST of sham saline (n=8), sham ethanol 
(n=9), ADX saline (n=10), and ADX ethanol (n=11) animals. (D) Ethanol increases 
3α,5α-THP immunoreactivity in the PVN of the hypothalamus after sham surgery and 
ADX, when compared to saline controls. (E) The red box indicates the location (-1.80 
mm relative to bregma) of representative photomicrographs within the PVN. (F) 
Representative photomicrographs (10x) of 3α,5α-THP immunoreactivity in the PVN. 
Ethanol or saline were administered 60 minutes prior to tissue fixation and collection. 
Data are expressed as mean positive pixels/mm
2 
± SEM. * indicates main effect of 
ethanol treatment, p < 0.0001. BNST, bed nucleus of the stria terminalis; PVN, 
paraventricular nucleus; Sham, sham adrenalectomy surgery; ADX, adrenalectomy. 
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Figure 3.5: Effect of ethanol (2g/kg, i.p.) on 3α,5α-THP immunoreactivity in the NAc 
shore (core/shell border) after sham surgery or ADX. (A) Ethanol decreases 3α,5α-THP 
immunoreactivity in the NAc shore after sham surgery and ADX, when compared to 
saline controls. (B) The red box indicates the location (1.60 mm relative to bregma) of 
representative photomicrographs. (C) Representative photomicrographs (10x) of 3α,5α-
THP immunoreactivity in the NAc shore of sham saline (n=8), sham ethanol (n=9), ADX 
saline (n=10), and ADX ethanol (n=11) animals. Ethanol or saline were administered 60 
minutes prior to tissue fixation and collection. Data are expressed as mean positive 
pixels/mm
2 
± SEM. * indicates main effect of ethanol treatment, p < 0.001 compared to 
saline administration. NAc, nucleus accumbens; Sham, sham adrenalectomy surgery; 
ADX, adrenalectomy. 
 
 
 
 71 
 
Figure 3.6: Effect of ethanol (2g/kg, i.p.) on 3α,5α-THP immunoreactivity in the CeA 
following sham surgery or ADX. (A) Ethanol decreases 3α,5α-THP immunoreactivity in 
the CeA after sham surgery and ADX, when compared to saline controls. (B) The red box 
indicates the location (-2.56 mm relative to bregma) of representative photomicrographs. 
(C) Representative photomicrographs (10x) of 3α,5α-THP immunoreactivity in the CeA 
of sham saline (n=8), sham ethanol (n=9), ADX saline (n=10), and ADX ethanol (n=11) 
animals. Ethanol or saline were administered 60 minutes prior to tissue fixation and 
collection. Data are expressed as mean positive pixels/mm
2 
± SEM. * indicates main 
effect of ethanol treatment, p < 0.0001 compared to saline administration. CeA, central 
nucleus of the amygdala; Sham, sham adrenalectomy surgery; ADX, adrenalectomy. 
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 EFFECTS OF VIRAL VECTOR MEDIATED P450SCC CHAPTER 4.
OVEREXPRESSION IN THE NAC OR VTA ON OPERANT ETHANOL SELF-
ADMINISTRATION 
 
INTRODUCTION 
Neuroactive steroids are neuromodulators synthesized in the brain that modulate 
neuronal activity and influence motivation and emotional behaviors. The GABAergic 
neuroactive steroid (3,5)-3-hydroxypregnan-20-one (3,5-THP or allopregnanolone) 
is a potent positive allosteric modulator of γ-aminobutyric acid type A (GABAA) 
receptors. GABAA receptors are the primary inhibitory receptors in the brain and mediate 
many of the behavioral effects of ethanol. Ethanol-induced increases of 3,5-THP 
contribute to many of the neurophysiological and behavioral effects of ethanol in rats 
(VanDoren et al., 2000; Hirani et al., 2002; Khisti et al., 2003; Hirani et al., 2005) as well 
as subjective effects of alcohol in humans (Pierucci-Lagha et al., 2005). Furthermore, 
human alcoholics have reduced blood plasma levels of 3,5-THP during alcohol 
withdrawal (Romeo et al., 1996). Moreover, increasing evidence suggests that 
modulating GABAergic neuroactive steroid levels may have therapeutic value for 
treating multiple neurologic and psychiatric disorders (Marx et al., 2006; Rasmusson et 
al., 2006; Morrow, 2007; Rupprecht et al., 2010; Brinton, 2013). 
Neuroactive steroids alter both ethanol reinforcement and ethanol consumption in 
rodents. For example, pregnenolone (Besheer et al., 2010a) and the synthetic GABAergic 
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neuroactive steroid  3α,5β-20-oxo-pregnane-3-carboxylic acid (PCA) (O'Dell et al., 2005) 
dose dependently reduce ethanol self-administration without producing sedation. 
Administration of 3,5-THP or the longer acting synthetic analog of 3,5-THP, 
ganaxolone, produce biphasic effects on ethanol self-administration (Janak et al., 1998; 
Ford et al., 2005; Besheer et al., 2010a). However, there are concerns that 3,5-THP 
and ganaxolone produce sedation (Belelli et al., 1989; Besheer et al., 2010a), limiting 
therapeutic effectiveness. The therapeutic potential of exogenously administered 3,5-
THP may also be limited by rapid metabolism (Purdy et al., 1990a).  
 Since the mesolimbic pathway is strongly implicated in ethanol reinforcement and 
consumption (Koob, 1992; McBride et al., 1999; Gonzales et al., 2004), and 
intracerebroventricular (ICV) administration of 3,5-THP alters mesolimbic dopamine 
release (Motzo et al., 1996; Rouge-Pont et al., 2002), we explored the possibility that 
neuroactive steroids alter ethanol self-administration via actions in these regions. To 
optimize therapeutic potential and produce long-term increases of neuroactive steroids, 
we used viral vector-mediated gene delivery to increase neuroactive steroid production in 
the nucleus accumbens (NAc) or the ventral tegmental area (VTA). The synthesis of 
neuroactive steroids requires cholesterol conversion to pregnenolone by the 
mitochondrial cytochrome P450 side chain cleavage (P450scc) enzyme, the rate-limiting 
enzymatic reaction in steroid synthesis. Therefore, we constructed a recombinant adeno-
associated serotype 2 (rAAV2) vector that overexpresses P450scc in vivo, which in the 
appropriate cell-type should lead to long-term elevations of neuroactive steroids that 
potentially increase GABAA receptor mediated neuronal inhibition. Not only did the viral 
 74 
vector manipulation result in chronically elevated P450scc expression, pregnenolone 
synthesis, and levels of 3,5-THP, but regionally specific P450scc overexpression 
significantly influenced long-term operant ethanol self-administration. We also used 
confocal imaging to determine cell-type specific localization of 3,5-THP in the VTA. 
MATERIALS AND METHODS 
Animals 
Adult male Wistar rats (~275 g) were obtained from Harlan Laboratories 
(Indianapolis, IN, USA) and used for characterizing viral vectors (n=16 for in vivo 
confirmation of P450scc overexpression; n=8 to examine effects of vector infusion on 
3,5-THP immunoreactivity in the NAc). The effects of rAAV2-P450scc transduction 
in the NAc on operant ethanol self-administration were assessed using adult male 
alcohol-preferring P rats bred in-house at the University of North Carolina at Chapel Hill. 
This stock of P rats was derived from breeders of the selected line of P rats provided by 
Indiana University (courtesy of Dr. T.K. Li). The effects of rAAV2-P450scc transduction 
in the VTA on operant ethanol self-administration and the double labeling experiments 
were performed using 2 cohorts of adult male P rats obtained from Indiana University. 
Baseline operant ethanol self-administration was comparable in all groups of P rats used 
for these studies. Animals were single housed in Plexiglass cages with food and water 
available ad libitum unless otherwise stated. The colony room was maintained on a 
normal 12 hr light-dark cycle (light onset at 0700 hr) and procedures followed National 
Institutes of Health Guidelines under University of North Carolina at Chapel Hill 
Institutional Animal Care and Use Committee approved protocols.    
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Apparatus 
Self-administration chambers 
 Operant ethanol self-administration was performed in conditioning chambers 
measuring 30.5 x 24.1 cm (Med Associates, Georgia, VT, USA) located inside sound-
attenuating cubicles. Cubicles were equipped with an exhaust fan for ventilation, which 
also masks external sounds. Both the left and right walls of the chambers contain a lever 
and liquid receptacle (i.e. 2 per chamber). The appropriate number of lever press 
responses simultaneously activates a stimulus light over the lever and a syringe pump 
(Med Associates) that delivers 0.1ml of liquid solution into a receptacle over 1.66 sec 
duration. Lever responses during reinforcer delivery were counted, but did not result in 
programmed consequences. The operant chambers were connected to a computer 
programmed to control sessions and record the resulting data. 
Locomotor chambers 
 Clear Plexiglas chambers (43.2 x 43.2 cm, Med Associates) with 16 photobeams 
per axis were used to measure locomotor activity. Total horizontal distance traveled (cm) 
was determined by the number of photobeam breaks during 30 minutes. Thigmotaxis was 
determined by measuring the percent of time spent in the center of the chamber compared 
to the perimeter of the apparatus. Photobeam breaks were collected via computer 
interface in 2 minute time intervals using Activity Monitor locomotor activity software 
(Med Associates).  
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Operant self-administration 
Training 
 The day prior to initial training, animals were water derived for approximately 24 
hr. Immediately following water deprivation, animals were placed in the operant 
chambers for a 16 hr lever press training session where 0.1ml of sucrose (10%, w/v) or 
water were concurrently available contingent on lever press responses. Lever press 
responses were initially maintained on a concurrent fixed-ratio 1 (CONC FR1 FR1) 
schedule of reinforcement and were gradually increased to CONC FR2 FR2 following 
delivery of 4 reinforcers, followed by a CONC FR4 FR4 schedule after delivery of 10 
reinforcers. Reinforcer presentations were paired with a light cue located above each 
lever. Following the 16 hr training session animals were returned to their homecage for a 
period of 24 hr with ad libitum water access thereafter.  
Sucrose fading, operant baseline sessions, operant self-administration testing 
 To facilitate lever pressing for ethanol a modified sucrose fading procedure 
(Samson, 1986) was used as previously described (Hodge et al., 1993; Besheer et al., 
2010b). Briefly, ethanol was gradually added to the 10% (w/v) sucrose solution and 
sucrose was faded out until only 15% (v/v) ethanol maintained lever responding. The 
sequence of sucrose/ethanol solutions were as follows: 10% sucrose/2% ethanol 
(10S/2E), 10S/5E, 10S/10E, 5S/10E, 5S/15E, 2S/15E, 0S/15E, with two sessions 
conducted at each concentration. Following sucrose fading, animals experienced a 
minimum of 28 baseline operant self-administration sessions with 15% ethanol versus 
water. Baseline and testing sessions were 30 minutes on an FR4 schedule of 
reinforcement. One week following surgery, animals that received rAAV infusion in the 
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NAc underwent 14 days of operant testing sessions. Animals that received rAAV 
infusion in the VTA underwent 21 days of operant sessions. Ethanol (95%, w/v, 
Pharmco-AAPER, Shelbyville, KY) was diluted in distilled water to 15% (v/v).  
P450scc AAV Plasmid Construction and Virus Packaging 
An AAV vector plasmid containing P450scc was created similarly as described 
elsewhere (Choi et al., 2006; McCown, 2006). In brief, the P450scc sequence was 
amplified from mRNA isolated from the rat olfactory bulbs and converted to cDNA using 
a SuperScript II reverse transcriptase kit (Life Technologies, Durham, NC, USA). The 
primers were designed to incorporate AgeI and NotI restriction sites in the 5’ and 3’ 
portion of the sequences, respectively. The sequences of the primers were as follows: (a) 
5’-ACCGGTATGCTGGCAAAAGGTCTT-3’, and (b) 5’-
GCGGCCGCTCATACAGTGTCGCCTTTTCTG-3’. The amplified PCR product was 
ligated into a TOPO TA vector as an intermediate step. Digestion of this intermediate 
vector with AgeI and NotI resulted in a P450scc cDNA fragment that was subsequently 
ligated into an AAV plasmid generously donate by Dr. Thomas McCown (University of 
North Carolina) containing a chicken β-actin promoter 5’ to the AgeI site to drive 
P450scc gene expression. Inverted terminal repeats (ITRs) flanked the β-actin promoter 
and P450scc cDNA sequence (Fig. 4.1B). This P450scc clone was sequenced to verify 
the integrity of the start and stop codons as well as the cDNA sequence. A single point 
mutation was noted that resulted in a non-polar valine to the smaller non-polar alanine at 
amino acid position 151. This mutation was further determined to be inconsequential as 
verified by increased mRNA and protein expression by reverse-transcriptase PCR and 
western blot, respectively, in transient transfected fibroblasts as well as assessment of 
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function via conversion of 22-hydroxycholesterol to pregnenolone via RIA. 
Subsequently, the recombinant AAV2- P450scc (rAAV2-P450scc) viral vector was 
packaged by the University of North Carolina (UNC) Viral Vector Core  (7.5 x 10
11
 viral 
particles/ml). AAV serotype 2 was used due to its previous success in infecting neuronal 
cells, long-term gene expression and minimal immune response. Control rAAV2-GFP 
vectors were also obtained from the UNC Vector Core (5 x 10
11 
- 1 x 10
12 
viral 
particles/ml). 
Cell culture 
Mouse L(tk-) fibroblast cells were used as described elsewhere (Harris et al., 
1995). Briefly, cells were grown in flasks previously coated with poly-l-lysine using 
Dulbecco’s modified Eagle’s medium (DMEM) with high glucose (Life Technologies, 
Durham, NC, USA) along with 10% fetal bovine serum and penicillin-streptomycin. 
Cells were maintained in a 5% CO2 humidified incubator. To test vector construct, cells 
were transiently transfected using Lipofectamine (Invitrogen).  
P450scc mRNA and Protein Analysis 
Cell and Tissue preparation 
Cell culture samples were washed with ice-cold phosphate buffered saline (PBS), 
scraped and pelleted down by low-speed centrifugation. Rats received either rAAV2-
P450scc or rAAV2-GFP infusions into the NAc or NAc shell and were sacrificed 1 (NAc 
shell) or 4 weeks (NAc) later. Brains were rapidly removed, flash frozen using 
isopentane, and stored at -80 Cº until processed. 
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mRNA analysis 
Total RNA was isolated from microdissected tissue using Trizol and converted to 
cDNA using SuperScript II (Invitrogen, Durham, NC, USA) with random hexamers. 
cDNA was amplified using the primer pair listed above under plasmid construction with 
a three step PCR program. Samples were subsequently separated using a 1.0% 
Tris/EDTA gel. cDNA samples were re-amplified using primers specific to β-actin 
(Whitman et al., 2013) for normalization. Gel images were acquired using a Fotodyne 
imaging cabinet (Fotodyne Inc., Hartland, WI, USA), and quantified using NIH Image 
1.57. Data were analyzed using Student’s t-test. 
Western blot analysis 
Microdissected NAc shell tissue was homogenized in a whole cell lysate buffer 
containing 1% sodium dodecyl sulfate (SDS), 1mM EDTA, and 10mM Tris. Protein 
concentrations were determined by a bicinchoninic acid protein assay. Samples were 
subsequently denatured and separated using SDS-polyacrylamide gel electrophoresis and 
transferred to polyvinylidene difluoride membranes (Invitrogen, Durham, NC, USA). 
Membranes were probed with an antibody against P450scc (Millipore, Billerica, MA, 
USA). Bands were visualized using enhanced chemiluminescence (GE Healthcare, 
Amersham, UK) under nonsaturating conditions. Blots were then re-exposed to an actin 
specific antibody (Millipore, Billerica, MA, USA) for normalization. Densitometric 
analysis was conducted using NIH Image 1.57, and data were analyzed using Student’s t-
test. 
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Surgery and viral vector infusion 
Animals were anesthetized with isoflourane and placed into a stereotaxic 
apparatus (David Kopf Instruments, Tujunga, CA, USA). The rAAV2-P450scc or control 
rAAV2-GFP vectors were infused bilaterally with a syringe pump (Harvard Apparatus, 
Holliston, MA, USA) and 10µl gastight syringes (Hamilton Company, Reno, NV, USA), 
connected with polyethylene tubing to needles made from stainless steel 30 gauge tubing 
(Smallparts Inc. Logansport, IN, USA). Needles and tubing were coated with 10% 
pluronic F-68 solution (Sigma-Aldrich, St. Louis, MO, USA) in order to minimize 
stainless steel binding of the virus. Virus was infused at a rate of 0.2µl/min and a total 
volume of 2-3µl/ hemisphere. Infusion coordinates relative to bregma were based on the 
rat brain atlas (Paxinos and Watson, 1998) as follows: NAc shell (AP + 1.6, ML ± 0.7, 
DV -7.5), NAc (AP + 1.6, ML ± 1.5, DV -7.5), VTA (AP - 5.5, ML ± 2.0, DV -8.3 with 
10º angle). Animals were given 1 week to recover from surgery before resuming operant 
self-administration. Animals lacking an expected P450scc mRNA/protein increase or 
with needle placements outside the injection target were excluded from statistical 
analysis. 
Immunohistochemistry (IHC) 
Tissue preparation 
Animals were anesthetized with pentobarbital (100mg/kg, i.p.; Professional 
Compounding Centers of America, Houston, TX, USA) and transcardially perfused with 
PBS followed by 4% paraformaldehyde. Tissue was post-fixed in 4% paraformaldehyde 
for 24hr at 4°C, sectioned coronally at 40μm on a vibrating microtome, and stored at -
30°C until further processing. 
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3α,5α-THP IHC 
 3α,5α-THP immunohistochemical assays were performed as previously described 
in detail (Cook et al., 2013). Briefly, No detergents or organic solvents were used to 
prevent the possibility of neuroactive steroid leeching. Free floating brain sections (3-4 
sections/animal/brain region) were rinsed, blocked, and incubated (48 hr at 4°C) in sheep 
affinity purified 3α,5α-THP antiserum (purchased from Dr. R.H. Purdy) at a dilution of 
1:2500 for 3,3’-diaminobenzidine (DAB) or 1:500 for fluorescent detection. A 
biotinylated secondary antibody (1:200; Vector laboratories, Burlingame, CA, USA) was 
used in conjunction with the Vectastain Elite ABC kit (Vector Laboratories, Burlingame, 
CA, USA) for DAB detection, using the manufacturers’ recommended procedures. An 
Alexa Fluor 488 secondary antibody was used for fluorescent detection (Life 
Technologies, Durham, NC, USA).   
3α,5α-THP IHC Cell Counts 
3α,5α-THP immunoreactivity with DAB detection was visualized using an 
Olympus CX41 light microscope (Olympus America, Center Valley, PA, USA) and 
images were captured with a digital camera (Regita model, QImaging, Burnaby, BC). 
Image analysis software (Bioquant Life Sciences version 8.00.20; Bioquant Life 
Sciences, Nashville, TN, USA) that utilizes linear integrated optical density was used for 
determining positive cell counts. The microscope, camera, and software were background 
corrected and normalized to preset light levels to ensure fidelity of data acquisition. 
Positive cell count measurements were calculated from a defined region (e.g., brain 
region), divided by the area of the region in square millimeters, and expressed as cell 
counts/mm
2
. Data were acquired from 4 sections/animal/brain region, and averaged 
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within a brain region for an individual animal to obtain one value per subject. 
Immunoreactivity was analyzed using Student’s t-test (Prism, GraphPad Software, La 
Jolla, CA, USA). Brain region analyses were performed using histological coordinates as 
follows: mPFC (+3.00 to +2.20 AP), NAc (+ 1.70 to + 1.00 AP), and VTA (-5.20 to -6.04 
AP). All analyses were based on coordinates relative to bregma in the Rat Brain Atlas 
(Paxinos and Watson, 1998). 
GFP and glial fibrillary acid protein (GFAP) epifluorescence 
Enhanced GFP (eGFP) immunofluorescence was used to determine the infection 
efficiency of the rAAV2 vectors. Sections were mounted on microscope slides, rinsed, 
blocked and incubated with eGFP primary antibody [(1:1000) Millipore, Billerica, MA, 
USA] applied directly to slides. Following rinses, the slides were incubated with an 
Alexa Fluor 488 secondary antibody (Life Technologies, Durham, NC, USA) for 1 hour 
at room temperature. Then, slides were rinsed and incubated with a fluorescent red nissl 
stain (Life Technologies) to identify neuroanatomical landmarks. GFAP 
immunofluorescence was used to determine needle placement of virus injections in the 
VTA of P rats. Briefly, free-floating sections were rinsed, blocked, incubated in GFAP 
primary antibody [(1:3000) Dako, Glostrup, Denmark] overnight at 4º C.  Sections were 
then rinsed and incubated with an Alexa Fluor 594 secondary antibody (Life 
Technologies). Immunofluorescence was visualized with a Leica DMIRB inverted 
microscope and images were captured with a Q-Imaging MicroPublisher camera and 
computer software (Surrey, British Columbia, Canada).  
 
 
 83 
Double immunofluorescent labeling and confocal microscopy 
Free floating sections were rinsed, blocked, and incubated in primary antibody for 
cell-type specific markers: TH [(1:1000), Immunostar, Hudson, WI, USA], NeuN 
[(1:200), clone 60, Millipore, Billerica, MA, USA], or GFAP (1:3000) for 24 hours at 4º 
C. Next, sections were rinsed, blocked, and incubated with 3α,5α-THP primary antibody 
for 48 hours at 4º C. Then, sections were rinsed and incubated with secondary antibody 
(Alexa Fluor 488 for 3α,5α-THP visualization and Alexa Fluor 594 for cell-type specific 
markers, Life Technologies). Immunofluorescence was visualized using a Leica SP2 laser 
scanning confocal microscope and computer software (Buffalo Grove, IL, USA). Cell-
type markers and 3α,5α-THP immunofluorescence were imaged sequentially to prevent 
fluorophore bleed-through. 
Radioimmunoassay (RIA) 
 Pregnenolone concentrations were measured using a procedure previously 
described in detail (Porcu et al., 2006), modified for use with cell media. Briefly, 
pregnenolone was extracted from cell media (spiked with 1000 counts per minute of [
3
H] 
pregnenolone for recovery) with 3 x 3ml of ethyl acetate, centrifuged at 3000g for 7 
minutes, and the resulting extracts were dried down. The samples were reconstituted in 2 
ml assay buffer, and 0.5 ml aliquots were removed for recovery and sample 
measurement. Pregnenolone antibody (MP Biomedicals, Orangeburg, NY) was added to 
samples along with pregnenolone standards. Values were determined using a one-site 
competition equation and corrected for extraction efficiency. 
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RESULTS 
The P450scc construct increases P450scc and the neuroactive steroid pregnenolone 
Overexpression of P450scc increases the rate limiting enzyme in steroid 
synthesis, thereby driving neuroactive steroid expression (Fig. 4.1A). In order to achieve 
this goal in vivo, P450scc gene expression was driven by a ubiquitous chicken β-actin 
(CBA) promoter in the context of an AAV vector (Fig. 4.1B). To confirm that the 
P450scc construct results in increases of P450scc and steroidogenesis in vitro, we 
transiently transfected mouse L(tk-) fibroblast cells and measured P450scc protein levels 
as well as pregnenolone levels in the cell media. Transfection of fibroblasts with the 
P450scc construct resulted in a 10-fold increase in P450scc protein expression at 48 hr 
post-transfection [t(4) = 11.74, p <0.001] (Fig. 4.1C), as well as an increase in 
extracellular pregnenolone levels [t(12) = 8.360, p < 0.0001] (Fig. 4.1D). 
Infusion of rAAV2-P450scc in the NAc shell increases P450scc 
To confirm that rAAV2-P450scc increases P450scc in vivo, we infused the 
rAAV2-P450scc or rAAV2-GFP vectors (2 or 4µl) into the NAc shell of Wistar rats and 
measured mRNA and protein levels 1 week following surgery. The infection efficiency 
of the rAAV2-GFP vector (2µl) and location of transduction within the NAc shell (Fig. 
4.2A) was determined 1 week post-infusion. The rAAV2-P450scc vector (4µl) increased 
P450scc mRNA by 573±122% [t(6) = 4.532, p < 0.005] (Fig. 4.2B) and protein levels by 
84±9% (2µl) [t(6) = 6.847, p < 0.005] or 172±69% (4µl) [t(6) = 2.479, p < 0.05] (Fig. 
4.2C). 
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Overexpression of P450scc in the NAc does not alter 3,5-THP or operant ethanol 
self-administration  
To determine if P450scc overexpression in the NAc alters ethanol reinforcement, 
we infused the rAAV2-P450scc or rAAV2-GFP vectors (3µl) into the NAc of P rats 
trained to self-administer ethanol. We have previously shown that ethanol decreases 
levels of cellular 3,5-THP in the NAc “shore” (core-shell border) (Cook et al., 2013), 
and others have shown that dopamine is released in the NAc shore during operant self-
administration of ethanol (Howard et al., 2009). Therefore, we aimed our viral infusions 
(3µl) at the NAc shore, which is also centralized within the NAc and thereby limits viral 
infection of surrounding brain regions (Fig. 4.3A). P450scc overexpression in the NAc 
did not alter operant ethanol responding (rAAV2-P450scc treatment [F (1,156) = 2.297, p 
= 0.1555]) (Fig. 4.3B) or ethanol intake (rAAV2-P450scc treatment [F (1,156) = 2.186, p 
= 0.1651]) during the 14 days of testing. Furthermore, there was no difference in water 
responding [F (1,156) = 0.0048, p = 0.9457] (Fig. 4.3B) or general locomotor activity 
[t(12) = 1.813, p = 0.0948] (Fig. 4.3C) between the rAAV-P450scc and rAAV-GFP 
groups. The rAAV-P450scc vector did, however, increase P450scc mRNA levels in the 
NAc 4 weeks following infusion [t(12) = 6.690, p < 0.0001] (Fig. 4.3D). To determine if 
rAAV2-P450scc infusion in the NAc increases 3α,5α-THP, we infused the rAAV2-
P450scc or control vector into the NAc of a separate group of Wistar rats and performed 
3α,5α-THP IHC at 1 week following infusion. IHC analysis revealed that rAAV2-
P450scc did not increase 3α,5α-THP in the NAc [t(6) = 0.1893, p = 0.86] (Fig. 3E-F). 
 
 86 
Overexpression of P450scc in the VTA reduces long-term operant ethanol self-
administration 
To test whether P450scc overexpression in the VTA alters ethanol reinforcement, 
we infused the rAAV2-P450scc or rAAV2-GFP vectors (2µl) into the VTA of P rats 
trained to self-administer ethanol. rAAV2-P450scc infusion in the VTA reduced ethanol 
responding by 20% (main effect of rAAV2-P450scc treatment [F (1,540) = 13.67, p < 
0.005]; main effect of time [F (20,540) = 2.785, p < 0.0001]) (Fig. 4.4B) and ethanol 
intake by 14% (main effect of rAAV2-P450scc treatment [F (1,540) = 8.174, p < 0.01]; 
main effect of time [F (20,540) = 3.092, p < 0.0001]) (Fig. 4.4C) over the 21 days of 
testing. Viral infusion did not affect water responding [F (1,540) = 0.4870, p = 0.4912] or 
general locomotor activity [t(27) = 0.5534, p = 0.5845] (Fig. 4.4D). There was a main 
effect of time on water responding [F (20,540) = 1.643, p < 0.05] due to higher water 
responding following surgery, which over the 3 weeks stabilized at a lower level for both 
groups. The reduction in ethanol reinforcement and consumption was associated with an 
increase in 3α,5α-THP positive cells in the VTA of animals that received rAAV2-
P450scc infusion [t(27) = 3.104, p < 0.005] (Fig. 4.4E-F). Since viral infusions may 
increase 3α,5α-THP in projection sites of the VTA, we also measured 3α,5α-THP 
immunoreactivity in the NAc and mPFC. There was no difference in 3α,5α-THP positive 
cells in the NAc [t(13) = 1.108, p < 0.28] or mPFC [t(13) = 0.7394, p < 0.47] of animals 
that received rAAV2-P450scc infusion in the VTA (data not shown).  
3α,5α-THP co-localizes with TH and NeuN in the VTA 
 To identify cell-types in which 3α,5α-THP is localized in the VTA, we used 
scanning laser confocal microscopy and double labeled with NeuN (neuronal marker), 
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GFAP (astrocyte marker), or TH (putative dopamine cell marker). We found that in the 
VTA 3α,5α-THP is located in neurons (Fig. 4.6A), but does not appear to be present in 
astrocytes (Fig. 4.6B). 3α,5α-THP was located in all TH positive neurons examined (294 
cells) as well as TH negative neurons (see arrows) (Fig. 4.6C). 
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DISCUSSION 
In the present study we developed a viral vector to overexpress P450scc, and 
drive long-term neuroactive steroid production in neurons that contain the necessary 
biosynthetic enzymes. We showed that P450scc overexpression in the NAc does not alter 
ethanol self-administration or local 3α,5α-THP levels. However, rAAV2-P450scc 
infusion in the VTA produced persistent reductions in ethanol responding and 
consumption over the 21 days of test sessions. The effects of rAAV2-P450scc 
transduction in the VTA were specific to ethanol responding since there was no effect on 
water responding or motor activity. Reduced ethanol self-administration was associated 
with a 36% increase in 3α,5α-THP positive cells in the VTA. However, 3α,5α-THP 
immunoreactivity was not altered downstream in the NAc or the mPFC. Taken together, 
it appears that rAAV2-P450scc infusion in the VTA produces long-term reductions in 
ethanol reinforcement and consumption by increasing GABAergic neuroactive steroids, 
including 3α,5α-THP locally within the VTA. Further investigation revealed that 3α,5α-
THP is localized to both TH positive and TH negative VTA neurons, but does not appear 
to be present in cells labeled with GFAP. 
The ability of rAAV2-P450scc transduction of VTA neurons to modulate ethanol 
drinking is likely due to modulation of neural circuitry via GABAA receptor-mediated 
neuronal inhibition. The available data suggests that increasing 3α,5α-THP within a cell 
reduces the excitability of that particular cell (Saalmann et al., 2006; Akk et al., 2007; 
Tokuda et al., 2010; Tokuda et al., 2011). Therefore, rAAV2-P450scc transduction of a 
cell most likely produces a presynaptic inhibitory effect. However, it is not clear how 
3α,5α-THP accesses the neuroactive steroid transmembrane binding sites on GABAA 
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receptors, but it has been proposed to be via intracellular (i.e. presynaptic) lateral 
diffusion  through the cell membrane (Akk et al., 2007) or by a paracrine or autocrine 
mechanism (Herd et al., 2007), as no active release mechanism has been identified. In the 
present study, we ascertained that 3α,5α-THP is located in TH positive dopamine neurons 
in the VTA, but we cannot rule out the possibility that glutamatergic or GABAergic 
neurons were also transduced. It is important to note that TH positive dopamine cells in 
the VTA co-release glutamate in the NAc shell during optical stimulation (Stuber et al., 
2010), therefore, rAAV2-P450scc transduction of TH positive neurons in the VTA may 
reduce glutamatergic as well as dopaminergic activity. A recently characterized group of 
TH positive VTA neurons that project to the lateral habenula (LHb) have been shown to 
produce reward when optically stimulated (Stamatakis et al., in press). Therefore, it is 
possible that ethanol reward was reduced by neuroactive steroid elevations in these LHb 
projecting cells of the VTA. Further experimentation will be needed to understand how 
local increases of 3α,5α-THP  in the VTA alter mesolimbic activity and identify cell-
types important in these effects. 
It is also likely that rAAV2-P450scc transduction of VTA neurons altered their 
response to ethanol in the operant self-administration procedure. Since ethanol is thought 
to disinhibit dopamine neurons (Spanagel and Weiss, 1999), increased 3α,5α-THP in 
these cells may prevent the ability of ethanol to produce this effect. However, rAAV2-
P450scc transduction of VTA may have also influenced 3α,5α-THP in glutamatergic 
afferent projection neurons from the prefrontal cortex or pedunculopontine tegmental 
nucleus (PPTg)/laterodorsal tegmental nucleus (LDT), for example. These neurons 
provide excitatory control over dopamine neurons, and if inhibited by increases of 3α,5α-
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THP, a decrease in dopamine neuron activity could be a possible outcome. In contrast, if 
3α,5α-THP is increased in the glutamatergic cells that synapse on the GABAergic 
interneurons, that inhibit dopamine neurons, we would expect an increase in 
dopaminergic activity. The bed nucleus of the stria teriminalis (BNST) sends both 
GABAergic and glutamatergic afferent projections to the VTA that predominately 
synapse on TH negative GABAergic neurons (Kudo et al., 2012). Optical stimulation of 
these projections produce opposing effects on reward and aversion (Jennings et al., 
2013), with stimulation of the GABAergic projection producing reward and stimulation 
of the glutamatergic projection producing aversive behavior. Therefore, although it is 
unclear how, increases of 3α,5α-THP in the VTA from BNST afferent projections may 
play a role in our behavioral results. It was recently shown that medium spiny neurons of 
the NAc that project to the VTA synapse on non-dopamine neurons (Xia et al., 2011). 
Therefore, it is difficult to determine what the effect of increased 3α,5α-THP in medium 
spiny neurons would be on dopaminergic activity. Taken together, there are several ways 
that increased intracellular 3α,5α-THP could diminish ethanol-induced dopaminergic 
activity and/or excitability via intracellular mediated neuronal inhibition.  
Alternatively, 3α,5α-THP could be “released” or diffuse to produce extracellular 
actions. If 3α,5α-THP is released from neurons in the VTA, the main theoretical 
consequence would be inhibition of interneurons. In contrast to reducing VTA dopamine 
cell activity, 3α,5α-THP inhibition of interneurons would likely increase dopamine 
activity (Tan et al., 2010). Site specific pharmacologic manipulations in the NAc and 
VTA suggest that reduced dopamine activity is associated with a reduction in the 
maintenance of operant ethanol self-administration in non-dependent rats [for review see, 
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(Gonzales et al., 2004)]. Therefore, it is unlikely that increased release of 3α,5α-THP was 
the predominant effect of rAAV2-P450scc transduction in the VTA. Finally, we cannot 
rule out the possibility that rAAV2-P450scc transduction of VTA involves several of 
these mechanisms resulting in the overall behavioral sequelae observed (Fig. 4.7). 
Targeting TH neurons selectively could overcome this limitation and help to determine 
the precise site of behavioral regulation by the enhancement of steroidogenesis in the 
VTA.  
The inability of rAAV2-P450scc transduction in the NAc to alter operant 
responding for ethanol may be due to an inability to increase 3α,5α-THP in NAc neurons 
that regulate ethanol self-administration. It is surprising that rAAV2-P450scc 
transduction in the NAc does not increase cellular 3α,5α-THP levels. Previous studies 
have shown dense cellular staining of 3α,5α-THP in the dorsal and ventral striatum 
(Saalmann et al., 2007; Cook et al., 2013), suggesting that the necessary biosynthetic 
enzymes are present in NAc neurons. However, we have recently shown that acute 
ethanol administration reduces 3α,5α-THP immunoreactivity in the NAc “shore” (core-
shell border), in contrast to many other brain regions that display an ethanol-induced 
increase of 3α,5α-THP (Cook et al., 2013). Therefore, regulation of 3α,5α-THP synthesis 
and/or metabolism may differ in the NAc, compared to other brain regions. Nonetheless, 
the observation that rAAV2-P450scc transduction of NAc did not alter local 3α,5α-THP 
levels or ethanol self-administration supports the idea that synthesis of GABAergic 
neuroactive steroids, including 3α,5α-THP may have been requisite for the effects of 
rAAV2-P450scc transduction of the VTA. 
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These studies underscore the importance of endogenous GABAergic neuroactive 
steroids in the regulation of neurotransmission across the brain, and potential for 
therapeutic manipulation.  Since these steroids are synthesized in brain circuitry and other 
endocrine organs, they provide a mechanism for interactions between many organ 
systems, integrating effects of all the neuroendocrine axes. It is not surprising therefore 
that alcohol use disorders are modulated by stress, gender, and neuroimmune processes 
that are all affected by neuroactive steroids. Since plasma 3α,5α-THP levels are reduced 
during withdrawal in human alcoholics (Romeo et al., 1996), this target merits further 
investigation. 
Genetic regulation of neuroactive steroid levels has multiple therapeutic 
advantages over systemic administration of neurosteroids or their analogs. First, the 
effects of rAAV transduction persists in the central nervous system at least 2 years in rats 
(Klein et al., 2002), 8 years in the rhesus monkey (Hadaczek et al., 2010), and is 
considered a permanent episomal modification of the genetic content of the cell. This is a 
critical factor for biomedical research examining chronic diseases such as addictive 
disorders. Next, it is possible to minimize untoward side effects by induction of 
steroidogenesis at sites that exhibit pathological activity, avoiding sites that confer 
unwanted neuroactive steroid effects. Indeed, we have recently found that chronic 
intermittent ethanol administration reduces neuronal 3α,5α-THP immunolabeling in the 
VTA, but not the NAc (Maldonado-Devincci et al., in preparation) and this effect is 
associated with increased ethanol self-administration (Lopez et al., 2008). Thus, our 
present data converge with other studies upon the conclusion that selective modulation of 
VTA neuroactive steroids modulate ethanol reinforcement and drinking. Therefore, the 
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combination of P450scc gene delivery with studies of brain activity could allow targeted 
therapy to manipulate persistent abnormal cellular activity that may underlie alcohol use 
disorders or other neurological and psychiatric disease. 
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FIGURES AND TABLES 
 
Figure 4.1: The P450scc construct increases functional P450scc expression resulting in 
elevated pregnenolone levels. (A) Model to enhance neuroactive steroid synthesis by 
overexpressing P450scc, which performs the limiting enzymatic reaction in 
steroidogenesis. (B) P450scc construct consisting of the P450scc gene driven by the 
ubiquitous chicken β-actin promoter flanked by inverted terminal repeats (itr). (C) 
Transient transfection of mouse (tk-) fibroblast cells increased P450scc by ~10-fold (p < 
0.001) 48 hr post-transfection. Representative immunoblot probed for P450scc with β-
actin used as a loading control, + indicates transfection with P450scc construct , - 
indicates control cells. (D) Pregnenolone levels were increased in the cell media (p < 
0.0001), measured by radioimmunoassay. * indicates p < 0.0001 compared to control. 
CBA, chicken β-actin; P450scc, P450 side chain cleavage; itr, inverted terminal repeat. 
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Figure 4.2: rAAV2-P450scc transduction in the NAc shell increases P450scc mRNA and 
protein expression dependent on the volume of virus infused. (A) Representative 
photomicrograph (10x) of rAAV2-GFP infection efficiency in the NAc shell 1 week after 
2µL rAAV2-GFP infusion (green=GFP, red=red nissl stain). The red box indicates the 
location of representative photomicrograph (+1.60 mm relative to bregma) within the 
NAc. (B) The 4µL infusion of rAAV2-P450scc significantly increased P450scc mRNA 
(p < 0.005) at 1 week post-surgery. Representative gel showing P450scc mRNA 
following 4µL rAAV2-P450scc or rAAV2-GFP infusion in the NAc shell. β-actin was 
used as a loading control. (C) rAAV2-P450scc transduction increased protein levels of 
P450scc following both the 2µL (p < 0.005) and 4µL (p < 0.05) infusions at 1 week post-
surgery. Representative immunoblot probed for P450scc following 4µL rAAV2-P450scc 
or rAAV2-GFP infusion in the NAc shell. P450scc is the uppermost band shown 
increased following rAAV2-P450scc transduction. β-actin was used as a loading control, 
but is not seen in the positive control (rat adrenal) due to the small amount of protein 
loaded (1µg) compared to brain samples.* indicates p < 0.05 compared to GFP control, 
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** indicates p < 0.005 compared to GFP control. NAc, nucleus accumbens; P450scc, 
P450 side chain cleavage; mRNA, messenger ribonucleic acid; rAAV2, recombinant 
adeno-associated virus serotype 2; GFP, green fluorescent protein.  
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Figure 4.3: rAAV2-P450scc transduction in the NAc increases P450scc mRNA but does 
not alter operant ethanol  self-administration or cellular 3α,5α-THP. (A) Representative 
photomicrograph (10x) of rAAV2-GFP infection efficiency in the NAc 1 week after 3µL 
rAAV2-GFP infusion (green=GFP, red=nissl stain). The red box indicates the location of 
representative photomicrograph (+1.60 mm relative to bregma) within the NAc. (B) 
rAAV2-P450scc transduction in the NAc did not alter operant ethanol responding or 
water responding, compared to rAAV2-GFP controls. Ethanol responding over the 14 
days of test sessions is collapsed in the bar graph. (C) rAAV2-P450scc transduction in 
the NAc did not alter total distance traveled (cm) in the open field test. (D) The 3µL 
infusion of rAAV2-P450scc significantly increased P450scc mRNA in the NAc (p < 
0.0001) at 4 weeks post-surgery. Representative gel showing P450scc mRNA level 
following 3µL rAAV2-P450scc or rAAV2-GFP infusion in the NAc. β-actin was used as 
a loading control. (E) Infusion of rAAV2-P450scc (3µL) in the NAc of Wistar rats did 
not alter 3α,5α-THP positive cells in the NAc at 1 week post-surgery. (F) Representative 
photomicrographs (10x) of cellular 3α,5α-THP immunoreactivity in the NAc 1 week 
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following 3µL rAAV2-GFP or rAAV2-P450scc infusion in the NAc. * indicates p < 
0.0001 compared to GFP control. NAc, nucleus accumbens; P450scc, P450 side chain 
cleavage; mRNA, messenger ribonucleic acid; rAAV2, recombinant adeno-associated 
virus serotype 2; GFP, green fluorescent protein. 
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Figure 4.4: rAAV2-P450scc transduction in the VTA produces long-term reductions in 
operant ethanol self-administration and increases 3α,5α-THP positive cells. (A) 
Representative photomicrograph (10x) of rAAV2-GFP infection efficiency in the VTA 1 
week after 2µL rAAV2-GFP infusion (green=GFP, red=nissl stain). The red box 
indicates the location of representative photomicrograph (-5.80 mm relative to bregma) 
within the VTA. (B) rAAV2-P450scc transduction in the VTA reduced operant ethanol 
(p < 0.005) but not water responding over the 21 days of test sessions, compared to 
rAAV2-GFP controls. Ethanol responding over the 21 days of test sessions is collapsed in 
the bar graph. (C) rAAV2-P450scc transduction in the VTA reduced ethanol intake 
(g/kg) (p < 0.01) over the 21 days of test sessions, compared to rAAV2-GFP controls. 
Ethanol intake (g/kg) over the 21 days of test sessions is collapsed in the bar graph. (D) 
rAAV2-P450scc transduction in the VTA did not alter total distance traveled (cm) in the 
open field test. (E) Infusion of rAAV2-P450scc (2µL) in the VTA increased 3α,5α-THP 
positive cells in the VTA (p < 0.005) at 4 weeks post-surgery. (F) Representative 
photomicrographs (10x) of cellular 3α,5α-THP immunoreactivity in the VTA 4 weeks 
 100 
following 2µL rAAV2-GFP or rAAV2-P450scc infusion in the VTA. * indicates p < 0.01 
and ** indicates p < 0.005 compared to control values. VTA, ventral tegmental area; 
P450scc, P450 side chain cleavage; rAAV2, recombinant adeno-associated virus serotype 
2; GFP, green fluorescent protein. 
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Figure 4.5: Localization of viral vector infusions was determined using GFAP 
immunofluorescence to visualize needle tracts. (A) Representative image showing GFAP 
immunofluorescence (red) at the needle tract and GFP positive cells (green) in the VTA 4 
weeks following rAAV2-GFP infusion. The red box indicates the location of the 
representative image (-5.20 mm relative to bregma) within the VTA. (B) Location within 
the VTA of rAAV2-GFP (green circle) or rAAV2-P450scc (black circle) infusions, 
relative to bregma. GFAP, glial fibrillary acidic protein; VTA, ventral tegmental area; 
P450scc, P450 side chain cleavage; rAAV2, recombinant adeno-associated virus serotype 
2; GFP, green fluorescent protein. 
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Figure 4.6: Confocal scanning microscopy revealed that 3α,5α-THP co-localizes with 
NeuN positive neurons, TH positive neurons, but not in GFAP positive astrocytes in the 
VTA of P rats. (A) 3α,5α-THP (green) co-localizes with NeuN (red) in the VTA. (B) 
3α,5α-THP (green) does not co-localize with GFAP (red) in the VTA. (C) 3α,5α-THP 
(green) co-localized with all TH (red) positive cells examined in the VTA (294 cells). 
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3α,5α-THP is also located in TH negative cells in the VTA (yellow arrows). NeuN, 
neuronal nuclei; VTA, ventral tegmental area; GFAP, glial fibrillary acidic protein; TH, 
tyrosine hydroxylase. 
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Figure 4.7: Simplified schematic of potential mechanisms of rAAV2-P450scc 
transduction-induced effects on VTA neurons believed to regulate ethanol reinforcement 
and consumption or in which optical stimulation is rewarding. Transduction of TH+ 
neurons may reduce activity in cells that project to (A) NAc, mPFC and/or (B) LHb or 
both sites. Transduction of afferent projections from (C) PFC, PPTg/LDT may decrease 
activation of TH+ projection neurons. Transduction of (D) BNST afferent projections 
onto GABAergic neurons have the potential to influence rewarding and/or aversive 
behavior. Transduction of inhibitory interneurons in the VTA is not expected to have any 
effect since biosynthetic enzymatic machinery is absent in these cells, but (E) increased 
extracellular levels of 3α,5α-THP may act via GABAergic interneurons to increase 
activity of TH+ neurons. VTA, ventral tegmental area; TH, tyrosine hydroxylase; NAc, 
nucleus accumbens; LHb, lateral habenula; PPTg/LDT, pedunculopontine tegmental 
nucleus/laterodorsal tegmental nucleus;. BNST, bed nucleus of the stria terminalis. 
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 GENERAL DISCUSSION CHAPTER 5.
 
 Alcohol use disorders continue to be pervasive in society and costly at many 
different levels. It is not just the individual that suffers but their families are damaged, 
children are born with fetal alcohol spectrum disorder, and far too many accidents and 
traffic fatalities are caused by alcohol disorders. Therefore, it is in everyone’s interest to 
develop efficacious treatments for alcohol use disorders. Determining specific effects of 
alcohol on the brain is critical to identify potential biological targets for therapeutic 
exploitation. A large body of data from basic research in whole animals (for review see, 
Morrow, 2007), in vitro physiology (Sanna et al., 2004; Tokuda et al., 2011), and human 
studies suggest (Pierucci-Lagha et al., 2005) that GABAergic neuroactive steroids 
contribute to the pharmacological effects of alcohol. It has been well documented that in 
rats ethanol increases levels of GABAergic neuroactive steroids. Since 3α,5α-THP and 
3α,5α-THDOC are very potent, producing pharmacological effects in nM concentrations, 
ethanol-induced increases of 3α,5α-THP and 3α,5α-THDOC can produce dramatic effects 
on brain activity. Furthermore, GABAergic neuroactive steroids can decrease ethanol 
consumption and alleviate withdrawal symptoms, making them attractive candidates as 
potential treatments for alcohol use disorders. Measures of steroids in brain tissue present 
significant challenges. Since steroids are not protein, standard laboratory measurements 
of protein or mRNA cannot be used. To further complicate things, steroids are lipid 
soluble, and the brain consists of a milieu of lipids. RIA and GC-MS measurements have 
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been developed to measure many steroids in blood plasma, but brain measurements are 
usually limited to the cerebral cortex and a few other regions highly enriched in steroids 
like the hippocampus and the olfactory bulb. Therefore, we have not been able to 
measure 3α,5α-THP in limbic/extended amygdala brain regions implicated in drug 
addiction disorders. Gain or loss of function studies are also difficult due to the fact that 
steroids do not come from genes, and there is not an antagonist for the neuroactive steroid 
binding sites on GABAA receptors. Therefore, the focus of this dissertation was to use 
innovative approaches to (1) examine ethanol-induced changes in 3α,5α-THP across the 
rat brain and determine if changes in 3α,5α-THP were due to peripheral or local actions 
(2) to use a viral vector to produce local brain changes in neuroactive steroids and 
measure effects on operant ethanol self-administration.  
 We showed that ethanol (2g/kg) produced divergent, brain region specific, 
changes in cellular levels of 3α,5α-THP. Many regions including the granule cells of the 
DG and the DMS that are densely labeled with 3α,5α-THP did not display a change in 
3α,5α-THP following ethanol administration. Therefore, the ethanol-induced changes in 
3α,5α-THP can be quite specific to particular cellular populations. For example, we 
observed an increase of 3α,5α-THP in the CA1 pyramidal cell layer, polymorphic cell 
layer of the DG, but not the granule cells of the DG. Since a reduction in 3α,5α-THP has 
not been reported previously in rats, the reductions of 3α,5α-THP in the NAc and the 
amygdala were surprising. Furthermore, cellular reductions of 3α,5α-THP were subregion 
specific, and isolated to the NAc “shore” (core-shell border) and CeA. Taken together, 
this work is in agreement with previous RIA and GC-MS experiments measuring 3α,5α-
THP in the whole cerebral cortex and hippocampus, and extends previous results by 
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showing that ethanol can increase or decrease cellular 3α,5α-THP in a brain region 
dependent manner. The presence of ethanol-induced reductions of cellular 3α,5α-THP are 
particularly intriguing. The mechanism(s) that underlie this reduction are unknown, but 
may involve regulation of 3α,5α-THP metabolism or diffusion/release from neurons. 
 The predominate theory in the field at the time of this study was that in vivo 
ethanol activates the HPA axis leading to release of 3α,5α-THP and neuroactive steroid 
precursor from the adrenal glands into the blood plasma, resulting in an increase of 
3α,5α-THP in the brain. The increase of 3α,5α-THP in the cerebral cortex has been 
shown multiple times to be dependent on the adrenal glands (Khisti et al., 2003; O'Dell et 
al., 2004; Porcu et al., 2004). Furthermore, our lab has shown that the increase of 3α,5α-
THP in the cerebral cortex is dependent on de novo StAR production in the adrenal 
glands as well as ACTH release from the pituitary gland (Boyd et al., 2010). Because of 
this body of work and limitations in steroid measurements, assumptions were made about 
how ethanol increased 3α,5α-THP in the rat brain. Specifically, it appeared that ethanol-
induced increases of 3α,5α-THP in the brain were due primarily to adrenal sources of 
3α,5α-THP and/or 3α,5α-THP precursor since 5α-DHP administration restores ethanol-
induced increases of 3α,5α-THP in the cerebral cortex following ADX. This is in stark 
contrast to in vitro experiments showing that ethanol bath application increases 3α,5α-
THP in hippocampal slices (Sanna et al., 2004; Tokuda et al., 2011). The presence of 
divergent changes or the lack of change in cellular 3α,5α-THP following ethanol ruled 
out the possibility that there is a global increase of 3α,5α-THP in the brain. Furthermore, 
the presence of divergent changes in 3α,5α-THP suggests that ethanol alters local 
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synthesis and/or metabolism of 3α,5α-THP in vivo, similar to the observation in 
hippocampal slices.  
 Evidence for ethanol regulation of local 3α,5α-THP synthesis also suggested that 
these effects might be independent of adrenal synthesis of 3α,5α-THP or its precursors. 
Since ethanol appeared to alter local levels of 3α,5α-THP, we tested this possibility using 
animals that had undergone ADX or sham surgery. We examined the effects of ADX on 
ethanol-induced changes in 3α,5α-THP only in the brain regions where we had 
previously observed an effect of ethanol. We showed that in the mPFC ethanol induced 
increases of 3α,5α-THP appear to be dependent on the adrenal glands since ethanol failed 
to elevate 3α,5α-THP following ADX. This effect is probably due to a lack of local 
precursor (Khisti et al., 2003), which under normal conditions is converted to 3α,5α-THP 
with increases of locally synthesized 3α-HSD and 5α-RI in the frontal cortex (Kim et al., 
2003).  
 In subcortical brain regions ethanol-induced increases (CA1 pyramidal cell layer, 
polymorphic DG, BNST, and PVN) and decreases (NAc shore and CeA) of 3α,5α-THP 
independent of adrenal gland activation. Therefore, we showed for the first time that 
ethanol alters local levels of 3α,5α-THP in vivo, which is likely due to local changes in 
brain synthesis and/or metabolism. The ability of ethanol to alter local levels of 3α,5α-
THP is not clear, but may be due to local brain region specific changes in levels of 
steroidogenic enzymes. There is evidence that ethanol increases levels of steroidogenic 
enzymes involved in 3α,5α-THP synthesis and the cholesterol transporter StAR mRNA in 
a brain region dependent manner (Kim et al., 2003). Following chronic ethanol there is 
also evidence for decreases in transcript levels of the GABAergic steroidogenic enzymes 
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3α-HSD and 5α-RI, which is associated concurrent reduction of 3α,5α-THP in the 
hippocampus (Cagetti et al., 2004). Therefore, it is possible reductions in steroidogenic 
enzymes may underlie the observed ethanol-induced reductions in 3α,5α-THP. Ethanol 
can also change the activity of GABAergic neuroactive steroid biosynthetic enzymes in 
mice, but changes in activity do not always predict 3α,5α-THP levels (Tanchuck et al., 
2009). Nevertheless, we cannot rule out the possibility that changes in enzyme activity 
may explain some of the current observations. Finally, as previously mentioned we 
cannot rule out the possibility that a reduction of cellular 3α,5α-THP is due to 
extracellular release. Future studies using microdialysis to investigate ethanol-induced 
release of 3α,5α-THP in the NAc shore or CeA could shed light on this possibility. 
 Other potential mechanisms that may explain brain region specific effects on 
3α,5α-THP levels include ethanol-induced increases of NMDA or locally generated 
acetaldehyde. For example, there is evidence in CA1 pyramidal cells that ethanol-induced 
increases of 3α,5α-THP are due to increased NMDA levels (Tokuda et al., 2011). This is 
based on the fact that the NMDA antagonist APV prevents ethanol-induced increases of 
cellular 3α,5α-THP using IHC, as well as ethanol depression of LTP. Furthermore, low 
levels of NMDA increase cellular 3α,5α-THP and depress LTP similarly to ethanol. 
Ethanol-induced increases of NMDA are somewhat surprising since ethanol has been 
shown to have antagonist properties at NMDA receptors (Lovinger et al., 1989).  
Interestingly, a subsequent study has shown that acetaldehyde produces similar effects on 
3α,5α-THP IHC and contributes to ethanol depression of LTP (Tokuda et al., 2013). 
Therefore, ethanol-induced increases of 3α,5α-THP in CA1 pyramidal cells may actually 
be due to effects of acetaldehyde and/or paradoxical increases of NMDA. 
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 Ethanol-induced changes in cellular 3α,5α-THP that we observed in subcortical 
brain regions likely contribute to behavioral and neurophysiological effects of ethanol, 
including synaptic plasticity. Multiple studies, both in vivo and in vitro suggest that 
3α,5α-THP contributes to the neurophysiological effects of ethanol (VanDoren et al., 
2000; Tokunaga et al., 2003a; Sanna et al., 2004). Evidence suggests that ethanol’s 
depression of LTP in CA1 pyramidal cells is due to increased cellular levels of 3α,5α-
THP (Tokuda et al., 2011). 3α,5α-THP administration mimics ethanol-induced deficits in 
hippocampal dependent spatial memory (Matthews et al., 2002). Furthermore, finasteride 
blocks ethanol-induced deficits on spatial memory (Morrow et al., 2003). Thus, 3α,5α-
THP induction in the hippocampus may contribute to ethanol-induced cognitive 
impairment. One of the characteristics of alcohol exposure is a change in synaptic 
plasticity in several key brain regions/neural circuits (for review see, McCool, 2011), 
which may contribute to alcohol dependence. 3α,5α-THP is localized in such a manner to 
directly modulate neural circuitry. Therefore, future studies should examine the 
contribution of 3α,5α-THP in ethanol effects on synaptic plasticity in other brain regions. 
 The current 3α,5α-THP IHC studies have raised compelling new questions that 
may further resolve the mechanisms underlying ethanol-induced changes in 3α,5α-THP. 
For example, in vitro studies using viral vector mediated RNA interference to silence 
gene expression may be able to parse out the role of specific biosynthetic enzymes or 
cholesterol transporters.  In the case of the pyramidal cells of the hippocampus we 
recapitulated the local action of ethanol on 3α,5α-THP levels in vivo, so it will be 
interesting to see if the novel in vivo results reported here can be recapitulated in vitro. If 
so, this may shed light on how ethanol-induced changes of 3α,5α-THP alter 
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neurophysiology in other brain regions, which ultimately may lead to studies aimed at 
understanding how changes in cellular 3α,5α-THP across the brain affect behavior.  
In our viral vector studies we used a rAAV2 vector to increase neuroactive steroids in the 
NAc and the VTA. This portion of my dissertation investigates sub-cortical brain regions 
where neuroactive steroids may act to alter ethanol reinforcement and consumption. Both 
3α,5α-THP and its synthetic analog ganaxolone can reduce ethanol self-administration in 
rodents. However, they also produce sedation and biphasic effects on ethanol self-
administration, both of which may limit their therapeutic potential. We chose to develop 
the rAAV2-P450scc vector to drive neurosteroidogenesis for several reasons. First, the 
conversion of cholesterol to pregnenolone by P450scc is the rate-limiting enzymatic 
process in steroid synthesis. Using a rAAV2 vector produces long-lasting expression of 
the gene of interest and is essentially a permanent episomal modification of the genetic 
content of that cell. Therefore, this approach is particularly well suited for examining 
long-term chronic disorders, such as alcohol use disorders. AAV2 also has the added 
benefit of being approved for clinical trials in humans. Finally, region specific 
transduction of P450scc may limit unwanted side effects of GABAergic neuroactive 
steroids and act specifically to reduce ethanol reinforcement and consumption. 
 The results from these studies showed that rAAV2-P450scc in the VTA reduced 
ethanol reinforcement and consumption over the 3 weeks of testing sessions, without 
altering motor behavior. This long-term reduction in ethanol self-administration was 
associated with a 36% increase in 3α,5α-THP positive cells locally within the VTA. 
Furthermore, we showed that 3α,5α-THP co-localizes in neurons, including TH positive 
putative dopamine neurons, but not in GFAP positive astrocytes. 
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VTA circuitry is well established in modulating motivation and reward. The most studied 
component of VTA circuitry in these processes is the mesolimbic dopamine pathway 
from the VTA to the NAc. Dopamine signaling plays a critical role in reward, motivation, 
and the establishment of stimulus-reward associations (Fouriezos et al., 1978; Wise et al., 
1978; Spyraki et al., 1982). Natural rewards such as food and sexual behaviors increase 
dopamine release in the NAc (Hernandez and Hoebel, 1988; Pfaus et al., 1990). Like 
most drugs of abuse, ethanol increases dopamine release in the NAc (Imperato and Di 
Chiara, 1986) and firing of dopamine neurons (Gessa et al., 1985). Furthermore, 
dopamine antagonists can reduce reinforcement of natural rewards (Spyraki et al., 1982), 
intracranial self-stimulation of rewarding electrical current (Fouriezos et al., 1978), and 
ethanol (Koob and Weiss, 1990). Due to the clear involvement of dopamine signaling in 
reward, the dopamine hypothesis of reward (Wise, 1978) and reinforcement (Fibiger, 
1978) were formulated. Over time the role of dopamine in reward and reinforcement has 
evolved. Studies have shown that dopamine signaling switches from activation by 
rewards to being time-locked to reward predictive stimuli (Ljungberg et al., 1992; 
Schultz, 1998). Therefore, dopamine signaling is thought to underlie cue-reward learning. 
In the case of ethanol self-administration, a single trial has been shown to shift dopamine 
signaling toward the predictive cue (Carrillo and Gonzales, 2011). The cellular 
mechanism that underlies cue-reward predictive learning may be enhanced glutamatergic 
synaptic strength onto dopamine neurons in the VTA (Stuber et al., 2008). Furthermore, 
administration of ethanol and other drugs of abuse strengthen excitatory synapses on 
dopamine neurons in the VTA (Saal et al., 2003). Moreover, ethanol biphasically alters 
glutamate release in the NAc of rodents (Moghaddam and Bolinao, 1994; Yan et al., 
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1998; Kapasova and Szumlinski, 2008) and blockade of metabotropic glutamate 
receptors in the NAc reduces ethanol reinforcement and consumption (Besheer et al., 
2010b; Cozzoli et al., 2012). Evidence suggests that GABAergic agonists and antagonists 
in the NAc  modulate ethanol self-administration (Hodge et al., 1995) and NAc dopamine 
release when infused in the VTA (Kalivas et al., 1990; Ikemoto et al., 1997). The effects 
of GABAergic drugs on ethanol self-administration and dopamine release are likely 
dependent on dose, cell-types inhibited, and subregion examined. Taken together, 
evidence suggests dopamine as well as glutamate and GABA transmission in the 
mesolimbic pathway contribute to reward and reinforcement. 
 The ability of increased cellular levels of 3α,5α-THP in the VTA to reduce 
ethanol reinforcement is likely due to GABAA receptor mediated inhibition of projection 
neurons. This is based on the fact that 3α,5α-THP and its biosynthetic enzymes are 
located in projecting neurons (Agis-Balboa et al., 2006; Saalmann et al., 2007), and 
increases of intracellular 3α,5α-THP levels result in inhibition of the cell in which they 
are produced (Akk et al., 2007; Tokuda et al., 2010; Tokuda et al., 2011). There are 
multiple ways in which increased 3α,5α-THP may reduce ethanol self-administration. 
Since a reduction in dopamine activity is associated with a reduction in the maintenance 
of operant ethanol self-administration in non-dependent rats (Gonzales et al., 2004), 
3α,5α-THP inhibition of VTA dopamine activity is a likely explanation for the current 
results. Increased 3α,5α-THP in TH positive dopamine neurons could endogenously 
inhibit the activity/reduce excitability of these cells. Similarly, increased 3α,5α-THP in 
TH positive neurons that project to the LHb could reduce ethanol reinforcement 
(Stamatakis et al., in press). Furthermore, increased 3α,5α-THP in glutamateric afferent 
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projections onto VTA neurons could reduce dopaminergic, glutamatergic or GABAergic 
activity. It is not clear how increases of 3α,5α-THP in projections from striatal medium 
spiny neurons or BNST neurons, both of which preferentially synapse on GABAergic 
cells in the VTA, would affect dopaminergic activity.  As previously mentioned, there is 
no known active release mechanism for 3α,5α-THP. However, we cannot rule out the 
possibility that 3α,5α-THP was released or diffused within the VTA, the result of which 
would differ from intracellular actions only by inhibiting GABAergic interneurons. This 
would theoretically result in an increase of dopaminergic activity. Although the precise 
mechanism is not clear, increased P450scc expression in the VTA reduces ethanol 
reinforcement, with increased 3α,5α-THP presumably playing a role in these effects. 
 Future studies may be able to clarify some of the uncertainties inherent to the 
current studies. A central question remaining is whether rAAV2-P450scc transduction of 
VTA neurons altered the activity of VTA circuitry. Future studies may be able to address 
this issue with electrophysiological measurements and/or measuring dopamine or 
glutamate release in the NAc as well as GABA release in the LHb under basal conditions 
as well as in response to ethanol. Ideally, these experiments would be performed in vivo, 
but in vitro electrophysiological studies would be useful for examining effects on 
synaptic plasticity, specific cell-types, or circuitry involved. 
 One of the limitations of our rAAV2 experiments is a lack of cellular specificity. 
Although rAAV2-P450scc infection will only produce increases of neuroactive steroids 
in cells that contain steroidogenic enzymes, it is not clear which cell-types produce the 
effects of VTA transduction on ethanol self-administration. We used a ubiquitous CBA 
promoter, which produces transduction of P450scc in all cells. To more precisely increase 
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neuroactive steroid levels a viral vector with a cell-type specific promoter could be used.  
For example, using a TH or glutamic acid decarboxylase (GAD) promoter would result in 
P450scc transduction only in cells that express TH or GAD. Therefore, increases of 
neuroactive steroids would only occur in TH or GAD positive cells. Another method that 
may compliment a cell-type specific promoter is the use of a vector with a reporter gene. 
Our viral construct did not include a reporter gene due to the size of the P450scc gene 
and the relatively small packaging size of AAV. The incorporation of a reporter gene 
would be useful for in vitro electrophysiological studies because cells infected by the 
vector could easily be identified and resulting functional changes evaluated.  
 Several psychiatric disorders have been associated with altered levels of 3α,5α-
THP (Marx et al., 2006; Rasmusson et al., 2006; Morrow, 2007; Rupprecht et al., 2010; 
Brinton, 2013). Translocator protein ligands increase cholesterol transport, resulting in 
increased steroidogenesis and GABAergic steroids. Recently, the translocator protein 
agonist XBD173 has shown promise for treating anxiety disorders in humans (Rupprecht 
et al., 2009). Historically, studies measuring 3α,5α-THP have mainly been limited to 
examining blood plasma levels in humans or whole cerebral cortex/hippocampus in 
animal studies. The studies contained in this dissertation employed techniques that can be 
used to examine cellular levels of 3α,5α-THP across the brain, and identify specific 
abnormalities that may contribute to pathological conditions. Therefore, 3α,5α-THP IHC 
may be useful in both translational studies in rodents and nonhuman primates as well as 
reverse translational studies examining pathological 3α,5α-THP levels in post-mortem 
human brain. Furthermore, drugs known to change 3α,5α-THP levels that are used 
therapeutically, such as selective serotonin reuptake inhibitors and antipsychotics may 
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also exhibit regional specificity on 3α,5α-THP levels in the brain, similar to the regional 
specificity of the effects of ethanol. Therefore, studying the anatomical localization of 
changes in 3α,5α-THP may reveal unknown and more precise biological targets for the 
treatment of CNS disease. 
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